Applications for Cyber Warfare: Genesis

Executive Summary:

The Air Force Research Laboratory (AFRL) is offering up to $99.99M per award through the Applications for Cyber Warfare: Genesis ARA to develop advanced cyber operations prototypes for transition to operational DoD platforms. White papers are accepted until September 29, 2030.

How much funding would I receive?

Typical awards range from $10M to $50M, with the possibility of awards up to $99.99M. Projects generally span up to 60 months.

What could I use the funding for?

Technologies of interest to the strategic vision of this ARA include, but are not limited to: platforms and architectures for the facilitation of cyber operations, command and control capabilities for the facilitation of cyber operations, effects based capabilities for the facilitation of cyber operations, predictive analysis capabilities for the facilitation of cyber operations, cross domain capabilities for the facilitation of cyber operations, intelligence gathering capabilities for the facilitation of cyber operations, intelligence processing capabilities for the facilitation of cyber operations, stealth delivery capabilities for the facilitation of cyber operations, stealth and persistence capabilities for the facilitation of cyber operations, and planning based utilities for the facilitation of cyber operations.

• Background: Technology Requirements

  The Air Force Research Laboratory is soliciting white papers under this Advanced Research Announcement (ARA) to research, design, develop, implement, and refine next-generation cyber warfare capabilities to advance the nation’s ability to prepare and fight wars as well as to build enduring advantages in Cyberspace.  This includes both cyber platforms and cyber weaponry.

  The Internet enables global connectivity, communication, and innovation. It has brought increased prosperity to the United States, inaugurating new industries and revitalizing old ones. It has also helped to ensure the superiority of the Joint Force, strengthening our ability to coordinate and quickly adapt to dynamic circumstances. In this decisive decade, the success of our Nation depends upon a free, open, and secure cyberspace.

  The Department of Defense’s (DoD) experiences have shown that cyber capabilities held in reserve or employed in isolation render little deterrent effect on their own. Instead, these military capabilities are most effective when used in concert with other instruments of national power, creating a deterrent greater than the sum of its parts. In this way, cyberspace operations represent an indispensable element of United States and Allied military strength and form a core component of integrated deterrence.

  The DoD will also use cyberspace operations for the purpose of campaigning, undertaking

  actions to limit, frustrate, or disrupt adversaries' activities below the level of armed conflict and to

  achieve favorable security conditions. By persistently engaging malicious cyber actors and other

  malign threats to United States interests in cyberspace, United States Cyber Command (USCYBERCOM) will support Department-wide campaigns to strengthen deterrence and gain advantages. As it campaigns in cyberspace, the Department will remain closely attuned to adversary perceptions and will manage the risk of unintended escalation.

  Among multiple lines of effort that are identified in the DoD’s most recent cyber strategy, two are particularly relevant to this solicitation:

  “Prepare to Fight and Win the Nation's Wars. The Department will campaign in and through

  cyberspace to advance Joint Force objectives. We will ensure the cybersecurity of the

  Department of Defense Information Network (DODIN) and conduct defensive cyberspace

  operations in order to protect it. The Department will enhance the cyber resilience of the Joint

  Force and ensure its ability to fight in and through contested and congested cyberspace. We

  will utilize the unique characteristics of cyberspace to meet the Joint Force's requirements and

  generate asymmetric advantages.”

  “Build Enduring Advantages in Cyberspace. The Department will pursue institutional

  reforms to build advantages that will persist for decades to come. We will optimize the

  organizing, training, and equipping of the Cyberspace Operations Forces and Service-retained

  cyber forces. We will ensure the availability of timely and actionable intelligence in support of

  cyberspace operations and explore the intersection of emerging technologies and cyber

  capabilities. We will foster a culture of cybersecurity and cyber awareness, investing in the

  education, training, and knowledge development of personnel across the defense enterprise.”

                                                        -2023 Summary, Cyber Strategy, US Department of Defense

  The purpose of this Advanced Research Announcement (ARA) is to research, design, develop, implement, and refine next-generation cyber warfare capabilities to advance the nation’s ability to prepare and fight wars as well as to build enduring advantages in Cyberspace.  This includes both cyber platforms and cyber weaponry.

  The scope and direction of this ARA are derived from these as follows:

  Preparing to win the nations wars - Capabilities researched, designed, developed, implemented, and refined under this Advanced Research Announcement will allow for:

  -Support to joint campaigns in and through cyberspace to reinforce deterrence objectives while achieving informational and military advantages. Adversaries of the United States will be made to doubt the efficacy of their military capabilities as well as the belief that they can conduct unattributed coercive actions against the United States. As the DoD campaigns in cyberspace for this purpose, offensive and defensive options will be furnished to support the Joint Force so that it is ready to respond rapidly across the spectrum of conflict.

  -The enhancement of cyber resilience of the Joint Force and ensure its ability to fight through contested and congested cyberspace. Prioritization will be given to those cyber capabilities that support the Joint Force's military mission assurance and commit to training the force to operate amid network and warfighting platform degradation.

  -The continual integration of state-of-the-art cyberspace operations platforms and weaponry. Further refinement of this approach, developing options that utilize the unique characteristics of cyberspace to meet the Joint Force's requirements and generate asymmetric advantages will occur throughout the lifecycle. This will include the pursuit of cross-domain effects during large-scale combat operations.

  Building Enduring Advantages in Cyberspace - Capabilities researched, designed, developed, implemented, and refined under this Advanced Research Announcement will allow for:

  -The prioritization of necessary reforms to meet the intelligence needs of the cyberspace operations community. Cyber requirements will be addressed through continued improvements to the business practices, human capital management, and organization of the Defense Intelligence Enterprise. Barriers to information sharing will be reduced and broader access to technical data consistent with applicable law, policies and procedures facilitated. Addressing gaps, ambiguities,

  and policy issues to enable intelligence activities in support of cyberspace operations will be facilitated.

  -The application and refinement of cyber platforms and weaponry. Technologies that can confound malicious cyber actors and prevent them from achieving their objectives in and through cyberspace will be prioritized. These include high assurance architectures and their associated technologies, advanced endpoint monitoring capabilities, tailored data collection strategies, automated data analytics, and systems that enable network automation, network restoration, and network deception.

  -The disruption and degradation of malicious cyber actors will be achieved through forward defense and by disrupting the activities of malicious cyber actors and degrading their supporting ecosystems.  These operations will be primarily conducted by USCYBERCOM, leveraging its authorities and in close coordination with other departments and agencies. A number of such operations have been occurring under this policy since 2018. Lessons learned from these operations inform pursuit of new capabilities and shape approached to risk management.  These operations will support the strategic approach outlined in the 2023 National Cybersecurity Strategy, in which the Department's cyberspace operations may complement concurrent actions by the diplomatic, law enforcement, and intelligence communities, among others. Together, these actions will support a whole-of-Government effort to reduce the perceived and actual utility of malicious cyber activity and render cybercrime unprofitable.

Are there any additional benefits I would receive?

Beyond the direct funding, awardees gain several indirect advantages:

Government Validation and Technical Credibility:
Winning an AFRL-funded cyber program signals that your technology meets high national-security thresholds—accelerating trust with primes, operators, and investors.

Enhanced Visibility and Notoriety:
AFRL awardees often receive recognition in government communications and defense-tech media, elevating your company’s profile in the cyber and national-security ecosystem.

Pathway to Follow-On Production:
OT prototype awards may transition to follow-on production contracts, enabling larger-scale procurement without a new competition—significantly increasing commercial value.

Stronger Valuation and Exit Potential:
Scaling cyber technologies under nondilutive funding, coupled with Air Force validation, can improve investor confidence and long-term acquisition potential in the defense tech sector.

What is the timeline to apply and when would I receive funding?

White papers may be submitted anytime before September 29, 2030, but AFRL recommends aligning with fiscal-year funding cycles:

• FY26: by December 30, 2025

• FY27: by September 30, 2026

• FY28: by September 30, 2027

• FY29: by September 30, 2028

• FY30: by September 30, 2029

Selected offerors will be invited to submit full proposals. Funding timing depends on fiscal-year availability but typically follows several months after invitation and review.

Where does this funding come from?

Funding comes from the Department of the Air Force, Air Force Materiel Command, through the Air Force Research Laboratory (AFRL), Rome Research Site.

Who is eligible to apply?

Eligible applicants include U.S. organizations capable of conducting advanced research and prototype development. Both FAR-based contracts and Other Transactions (OTs) may be awarded. There is no set-aside, allowing large businesses, small businesses, and research institutions to participate.

What companies and projects are likely to win?

Competitive submissions will:

• Demonstrate strong capability to develop cyber operations prototypes

• Present feasible transition paths to DoD operational platforms

• Show technical merit and alignment with cyber dominance objectives

• Provide credible teams with relevant cyber R&D and integration experience

Projects focused on scalable, operationally relevant cyber capabilities with clear transition potential are most likely to receive funding.

Are there any restrictions I should know about?

• Awards may be issued as either FAR-based contracts or Other Transactions (OTs) under 10 USC 4021–4023. Each mechanism has different compliance requirements and follow-on potential, especially for successful prototype efforts .

• While technical and contracting discussions are allowed, communications with AFRL do not constitute a government commitment to fund or award any proposal. Only Contracting Officers can legally bind the government .

• Applicants are cautioned that failure to follow proposal formatting or submittal instructions may result in lower evaluation ratings or rejection .

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive white paper will likely take 20–50 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

Our full service support is available for the white paper for $5,000.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Access the funding announcement here.

CIRM CLIN2: Funding Opportunity for Clinical Trials

Executive Summary:

CIRM’s CLIN2 program provides up to $15M to advance interventional Phase 1–3 clinical trials for stem cell–based and genetic therapies addressing serious unmet needs. Applications are accepted quarterly, with 2026 deadlines falling on the last business day of January, April, July, and October at 2:00 PM PST.

How much funding would I receive?

Funding depends on the stage of your clinical trial:

• First-in-Human: Up to $8M (for-profit) / $12M (non-profit)

• Phase 2/Subsequent Phase 1: Up to $15M

• Phase 3/Pivotal: Up to $15M

What could I use the funding for?

The CLIN2 award supports completion of an interventional phase 1, 2 or 3 clinical trial for a stem-cell based or genetic therapeutic candidate and may also fund an associated natural-history comparator or lead-in normal healthy volunteer study. Applicants are encouraged to use accelerating trial designs where appropriate, such as basket trials or adaptive design dose-escalation protocols.

The CLIN2 Program aims to advance clinical candidates that have the potential for transformative patient impact and that address barriers to access and affordability. To support this goal, align with Proposition 14’s mandate, and remain responsive to an evolving scientific and regulatory landscape, funding preferences will be set on an annual basis. These preferences will be guided by portfolio analyses and other strategic considerations in a cyclical manner.

For fiscal year 2025-2026 CLIN2 cycles, the following modalities and project features will be prioritized:

• Pluripotent stem cell-derived therapies

• In vivo genetic therapies

• Therapies using non-viral nucleic acid delivery

• Projects addressing diseases of the brain and CNS

• Applications from California organizations

• Projects progressing from CIRM-funded IND-enabling or earlier phase clinical trial awards

• Projects with Fast Track, RMAT or Breakthrough designations

• Projects proposing pivotal clinical trials (as agreed-to by the FDA)

• Required Activities

  • All clinical operations activities needed to complete the trial according to the proposed timeline

  • Outreach, enrollment, and retention activities to achieve trial enrollment demographics reflecting the target patient population

  • Treatment of patients with the therapeutic candidate (or control) and follow-up visits per the clinical protocol

  • Sharing of any non-clinical as well as clinical data per the CIRM data sharing requirements

  • Establishment and regular convening of a Strategic Planning Committee (SPC) with clinical development expertise to provide forward-looking strategic advice

  • Activities associated with managing, preserving, and sharing data and knowledge from the study

  • Activities associated with access and affordability planning for the therapeutic candidate in the proposed indication

• Allowable Activities

  • Natural history studies needed for baseline or control data for the interventional trial

  • Lead-in studies in normal healthy volunteers for the interventional trial

  • Studies to develop biomarkers, understand mechanisms of action and develop a potency assay

  • Regulatory activities including FDA interactions and requests for designations

  • Non-clinical studies required by the FDA (FDA documentation required)

  • Strategic planning activities

  • Manufacturing activities to supply the current clinical trial, including technology transfer and FDA-approved comparability studies, if needed

• Conditionally Allowable Activity

  Manufacturing for the next phase trial. Funding of that activity will be conditioned on 1) an interim evaluation by CIRM and a panel of independent experts of the clinical trial data to date, and 2) provision of 50% co-funding for this activity, if co-funding is required as specified in “Award Amount and Duration” below

• Unallowable Activities

  • Costs incurred on or before the date of ICOC approval

  • Discovery or translational research

  • Activities already budgeted or paid for under a prior, existing or future CIRM award

  • The costs of activities performed by a separate out-of-state organization that retains intellectual property or independent publication rights in any intellectual property (e.g., invention, technology, data) arising out of the CIRM-funded project

Are there any additional benefits I would receive?

Government Validation and Credibility
CIRM’s rigorous review provides a powerful credibility signal to investors, strategic partners, and clinical collaborators.

Enhanced Visibility and Notoriety
Awardees benefit from increased recognition through CIRM communications and visibility across the state’s stem cell and gene therapy ecosystem.

Access to CIRM’s Specialized Infrastructure

• Alpha Clinics Network for trial acceleration and patient access

• GMP Manufacturing Network for cell and gene therapy manufacturing

• Industry Resource Partners including preferred CROs and CDMOs

Stronger Exit and Valuation Potential
Nondilutive capital allows companies to advance high-value programs without dilution, often increasing valuation and improving partnership or acquisition outcomes.

What is the timeline to apply and when would I receive funding?

Applications Accepted: Quarterly

• 2026 Deadlines: Last business day of January, April, July, October at 2:00 PM PST

• GWG Scientific Review: ~90 days after deadline

• Board Approval: ~60 days after review

• Project Start: Within 60 days of approval

Total time from submission to project kickoff: ~6 months.

Where does this funding come from?

Funding is provided by the California Institute for Regenerative Medicine (CIRM) through Proposition 14, which supports the advancement of stem cell and genetic medicine programs statewide.

Who is eligible to apply?

For-profit or non-profit organizations

1. FDA-cleared IND (or submitted IND for CIRM-funded programs with clearance within 30 days)

2. PI with ≥15% effort

3. Project Manager with ≥50% effort

4. Data Project Manager

5. Applicant must be the IND sponsor

6. At least one California trial site

7. Must begin work within 60 days of board approval

8. Must meet co-funding and solvency requirements

What companies and projects are likely to win?

CIRM scores applications across five scientific merit categories:

1. Value Proposition – Whether the therapy offers meaningful clinical improvement over existing options, addresses unmet need, and is practical for real-world uptake by patients, providers, and payors.

2. Scientific Rationale – Strength of the biological justification, robustness of supporting data, and evidence of disease-modifying activity from relevant models or prior clinical studies.

3. Project Plan & Design – Whether proposed activities efficiently advance development, enable clear go/no-go decisions, support timely enrollment, include appropriate manufacturing plans, and can be delivered within the proposed budget, timeline, and risk-mitigation strategy.

4. Team & Resources – Expertise and coordination of the project team, access to required facilities (including manufacturing), and track record with stem cell or gene therapy programs.

5. Population Impact – Understanding of the affected population and strength of plans for representative outreach, enrollment, and retention.

Are there any restrictions I should know about?

No funding for discovery or early translational research:

1. No pre-approval costs

2. No out-of-state work where the external organization retains IP/publication rights

3. Co-funding required for for-profits (30–50%)

4. Only one CLIN2 application per PI per cycle

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive proposal will likely take 150–250 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

Our full service support is available for $15000 Initial Fee + a 3% Success Fee.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

View the Funding Announcement Here.

USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development

Executive Summary:

United States Special Operations Command (USSOCOM) is awarding $2,000,000 to $10,000,000 for projects across defined Research Areas of Interest (RAIs) to advance biomedical, human performance, and canine medicine relevant to Special Operations Forces. This BAA is open continuously through 31 July 2028; applicants must first submit a pre-proposal via eBRAP and, if invited, a full application (generally within 60 days of invitation).

How much funding would I receive?

1. Typical project size: $2 Million to $10 Million

2. Program capacity: “Anticipated total costs… will not exceed $20 Million annually” across all awards funded under this BAA.

What could I use the funding for?

A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel (medical devices, drugs, and biologics) to support far-forward early intervention of life-threatening illnesses or injuries within an Irregular Warfare or asymmetric, multi-domain operational environment. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. The equipment must be simple to employ, require minimum maintenance, and have low power consumption. Drugs and biologics should optimally not require refrigeration or other special handling. All materiel solutions must be capable of commercialization. Research projects may apply existing scientific and technical knowledge for which concept and/or patient care efficacy have already been demonstrated to meet SOF requirements. The proposed research must be relevant to active-duty service members, veterans, military beneficiaries, and/or the American public. Relevant research must be responsive to the health care needs of the U.S. Armed Forces, family members of the U. S. Armed Forces, and U.S. Veterans.

Proposals must address a relevant health problem responsive to one of the Research Areas of Interest below (Clinical trials are normally not funded by this BAA):

• Damage Control Resuscitation (DCR)

  SOF medical personnel require capabilities for far-forward medical care to reduce the mortality and morbidity associated with critical wounds and injuries. The proposed research, application, and/or development of medical techniques and materiel (medical devices, drugs, and biologics) for optimal triage and early intervention in critical life-threatening injuries when casualty evacuation is not possible or is delayed. The project areas under DCR to which the USSOCOM will give highest consideration are:

  • Global Treatment Strategies and Next Generation Wound Management:
    The proposed project must research, apply, and/or develop effective treatment strategies that address the following elements: resuscitation, optimal resuscitation fluid(s), uncomplicated shock, noncompressible hemorrhaging, traumatic brain injuries, and austere damage control surgery. These strategies must be optimized for medics in austere, far-forward areas, with minimal logistical or specialty support, who must stabilize and treat patients for extended periods (days, not hours). Projects that research and develop an all-in-one traumatic wound care treatment that can achieve hemostasis, and incorporate analgesia are preferred.

  • Analgesia:
    The proposed project must research, apply, and/or develop novel, safe, efficacious, peripherally, and centrally acting analgesia that provide easy administration in the field, tolerance of extreme environments, and effectiveness at the point of injury for a prolonged period of field care (days, not hours) and does not sensitize the patient to topical analgesia. Maximum analgesia with minimal sedation is preferred.

  • Far Forward Blood, Blood Components, Blood Substitute, & Injectable Hemostatics:
    The proposed project must research novel strategies to increase the ease, efficacy, and safety of blood transfusions (i.e., person to person, pre-hospital blood banking, rolling blood banks, and blood substitutes) forward of normal logistics support; (e.g., evaluating blood for type/cross matching and for the presence and/or reduction of pathogens, leucocytes, and AB antibodies to improve safety of whole blood transfusion at the point of injury). Projects that will be considered also include injectable medications to address the coagulopathy of trauma and novel strategies to improve tissue oxygenation.

  • Austere Surgical Stabilization:
    Future theatres where SOF personnel will operate are likely to be much less medically robust than the past decade of fighting in our current theatres (this can translate to remote civilian areas), and there will be a mismatch between capability and need. Rather than sitting at hardened structures waiting on patients, surgical personnel may be increasingly asked to go to the patient. Research should focus on mobility/portability of medical and surgical equipment, including support equipment such as sterilization, with emphasis on equipment with greater capabilities than currently fielded devices, smaller size and weight, low power demands, and flexibility in power supplies. Additionally, research and development efforts should include telehealth technologies linking forward surgical providers with higher medical authority consultation and effective, relevant, and dynamic surgical training capabilities. Lastly, research into future procedures and devices may also include a human systems approach to define limitations and mitigation strategies of surgical capability in austere environments (i.e., low light, temperature variability, improving surgical access in distributed maritime environment, surgery in flight, etc.) to bridge time to surgery when patient load exceeds surgical capability.

• Prolonged Field Care (PFC)

  SOF medical personnel require capabilities for far-forward medical care to reduce the mortality and morbidity associated with critical wounds, injuries, diseases, and associated sepsis. PFC should focus on novel treatments that support the ability to manage 3-5 patients across the spectrum of illness to multi-system injury for a minimum of 5-7 days. SOF medical personnel require capability to expedite evacuation and increase survivability with limited site of injury support in austere environments including: hyperbaric, mountainous, high-altitude, arctic, and distributed maritime operations.

• Medical Sensors and Devices

  The primary emphasis is to research, apply and/or develop field-sustainable, rapidly deployable medical sensors and/or devices for extended care beyond initial trauma resuscitation, to include austere/forward surgery while operating in areas where casualty evacuation is delayed or unavailable. In addition, proposals that investigate or develop wireless biosensors should demonstrate physiological monitoring capabilities to include, but not limited to, heart rate, blood pressure, pulse oximetry, respiration rate, capnography, core temperature, heart rate variability and compensatory reserve index (CRI). Research and development of devices and sensors should include or plan for the capability to transmit (Bluetooth 4.2) to Android handheld devices and be designed with an open architecture to allow for sensors to be incorporated into a family of sensors that may or may not report to a central handheld device. (NOTE: Ideally, sensor and equipment technologies should be electronically readable, scannable, or transmittable to the Battlefield Assisted Trauma Distributed Observation Kit (BATDOK), an Android-driven, multi-patient, point of injury casualty monitoring capability being fielded by U.S. Air Force (USAF) Pararescuemen and other SOF Medics. Novel devices are required which aid in measuring physiologic decompensation and/or adequacy of treatment/resuscitation in the field environment and/or provide a trigger for a pre-hospital medical intervention (i.e., validation of tissue (muscle) oxygen saturation (StO2), CRI, traumatic brain injury (TBI) measures, etc.

• Portable Lab Assays and Diagnostics

  The proposed project must research, apply and/or develop novel concepts for portable and environmentally stable far forward laboratory assays and diagnostics. Equipment should be extremely portable, ruggedized, use limited or no external power, and any reagents should be self- contained and stable in extreme environmental conditions. Preference will be given to proposals that are field oriented, rugged, low weight/cube space and have little to no refrigeration requirements. Additionally, novel wireless, transmittable or scannable solutions such as patches, scanner/readers or other noninvasive technologies are encouraged.

• Force Health Protection and Environmental Medicine

  SOF personnel must often operate for extended periods of time in austere environments that expose them to extremes in altitude, temperature, humidity, wind, kinetosis, infectious diseases, toxic industrial chemicals, toxic industrial materials, and environmental hazards (including envenomation). In addition, the environment may be compromised due to chemical, biological, and radiological contamination. The primary emphasis of this research area is to research, apply, and develop techniques, therapeutic measures, and materiel (personal protective equipment (PPE), medical devices, drugs, and biologics) to ensure sustained human performance and effectiveness while operating in harsh environmental conditions and/or wearing appropriate PPE.

  • Chemical, Biological, Radiological, Nuclear, and Explosive (CBRNE) Rapid Diagnostics, Treatment, and Prophylaxis:
    The proposed projects must research, apply, and/or develop novel approaches that will diagnose, treat, and protect SOF personnel from exposure to chemical, biological, radiological, nuclear, and high yield explosives in near real time.

  • Occupational and Environmental Health (OEH) Hazards:
    The proposed project must focus on development of novel methods and devices for rapid identification and analysis of exposures to OEH hazards. Research must support the development and analysis of handheld, field hardened, and environmentally stable analytical devices, monitoring devices, dosimetry, assays for rapid on-site identification, and real-time analysis of OEH hazards in air, water, and soil that could pose an acute or chronic health hazard to SOF personnel. Such OEH hazards include toxic industrial chemicals/toxic industrial materials (TICs/TIMs), lead exposures, food and water borne pathogens, toxins, biological agents, and radiological material exposures.

  • Operational Exposure Monitoring:
    The proposed project must seek to develop wireless biosensors for monitoring SOF personnel in extreme environments (i.e., high altitude, whether in-flight or the environment itself, excessive heat or cold, etc.), and potentially hazardous material exposure. Sensors should address physiological measurements and/or chemical, biological and/or radiological hazards. For hazards monitoring, a personal dosimetry device is desired that can detect and alarm based on radiation and chemical presence. The alarming function can be pre-determined to account for known environmental conditions (i.e., natural occurring radiation levels that are below threshold/detrimental health levels) and parts per million (PPM) counts that would trigger an alert. This detection device needs to be able to alarm differently to identify the "type" of hazard(s), and to trigger a back-off and/or donning of additional PPE. Monitoring should be capable of wirelessly communicating via Bluetooth 4.2 to Android handheld devices, tablets, or compatible wrist-mounted displays.

• Brain Health

  Brain Health research efforts include, but are not limited to: determining if repeated low-level blast exposure (rLLBE) causes brain injury or repeated blast brain injury (rBBI), development and validation of fieldable Neurocognitive Assessment Tools (NCATs) and baseline testing, Comprehensive Symptom History (CASH) collection, blast exposure and impact monitoring, determination of safe acceptable limits for blast exposure, development and validation of capabilities to easily identify/diagnose rBBI, methods to prevent, screen for, monitor, and correct neuroendocrine dysfunction. Additionally, Brain Health research efforts include, but are not limited to: methods to prevent TBI from impact and blast such as redesign of helmets, body armor, and munitions, development of pharmaceuticals to prevent and/or treat brain injury, validation of brain injury prevention strategies, and development of return to duty decision support tools.

  • Environmental Exposures Protection:
    Research that develops novel material and/or approaches to protect SOF personnel from the neurological effects of single and repetitive auditory (impulse noise) and non-auditory (overpressure) blast exposures and other environmental factors determined to affect nervous system function.

  • Environmental Exposure Effects:
    Research that determines the neurocognitive, nervous system, and auditory effects from single and repeated low- and high-level blast exposures, impulse noise, and other potential hazardous environmental factors.

  • Biomarkers:
    Research to determine which biomarkers are indicative of rBBI; sequelae from rBBI causing further injury; recovery status; and recovery rate from rBBI. Testing and validating diagnostic biomarkers for rBBI. Proposals should also consider incorporation of validated biomarkers onto existing or future diagnostic platforms. Use of machine learning and/or model development to interpret and report biomarkers that are indicative of rBBI are of interest.

  • Neuropsychological Testing:
    Research to validate neurocognitive assessment tools (NCATs) to determine baseline neurocognitive status, readiness, neurocognitive degradation, sensitivity to various exposures, TBI and recovery status post injury. Proposals to improve the speed, accuracy, specificity, and proximity to injury for the use of NCATs, as well as to compare new technologies and/or modalities (including passive assessment of cognition) to existing NCATs.

  • Olfactory, Oculomotor, Auditory, Vestibular, Cranial Nerve, and Vocal-Acoustic Performance:
    Research and proposals to perform and validate oculomotor, auditory, vestibular, cranial nerve, and vocal acoustic assessments. Research and proposals to assess the effect of nervous system injury to oculomotor, auditory, vestibular, cranial nerve, and vocal-acoustic performance and strategies to restore their performance after injury and prevent injury or further decline.

  • Postural Stability:
    Research to assess the effects of blast exposure on postural stability including the proprioceptive component. Novel treatment strategies, therapies, and therapeutics to prevent and/or correct detriment to postural stability from TBI and neurotrauma caused by blast, impact, and/or other environmental exposures.

  • Neuroendocrine Dysfunction:
    Methods to prevent, screen for, monitor, and correct neuroendocrine dysfunction.

  • Neuroimaging:
    Research into novel imaging and imaging interpretation techniques including, but not limited to computed axial tomography (CAT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans, to diagnose brain tissue pathologies including, but not limited to, axonal injury, myelin injury, and interface astroglial scarring without the need for immunohistochemistry, immunofluorescence, or histopathology testing.

  • Analytics:
    Research into analysis including machine learning, natural language processing, and artificial intelligence enabled analysis of data including, but not limited to, NCATs; environmental exposures likely to affect brain health; blast, impact, and noise exposures; auditory, vestibular, and vocal acoustic assessments; postural stability assessments; and neuroimaging.

  • Neuromodulation:
    Research into the use of neuromodulation techniques for treating TBI, neurotrauma, pain, restoring and improving function, improving behavioral health, and cognitive performance.

  • Brain Lymphatics and Glymphatics:
    Research into measuring the fluid dynamics of the brain lymphatic system, diagnosing dysfunction, and validation for tools or techniques to improve brain lymphatic clearance.

  • Pupillometry, Pupillary Response, and Microsaccades:
    Research into field capable pupillary response measurement capture and analysis, with or without the ability to capture Microsaccades to assess central nervous system loading and/or damage.

• Automation of Systematic Reviews and Metanalysis

  Research into Automation of Systematic Reviews and Metanalysis using the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) or a similar method

• Human Performance

  USSOCOM requires SOF personnel to withstand extraordinary physical demands and psychological stress to complete their missions. The optimization of SOF personnel’s ability to perform at very high levels for long durations, in addition to processing information and making critical decisions in a timely manner, while operating in extreme environments, will significantly improve their overall operational effectiveness. This research area explores alternatives and/or new approaches to sustain and optimize SOF human performance both to increase mission capability and to extend the career longevity of SOF personnel.

  • Improved Sleep:
    The proposed project must research, apply and/or develop novel approaches to achieve the restorative effects of sleep. This may include methods to induce, maintain, or improve the quality of sleep throughout the entire night. Additionally, the ability to accelerate the effects of sleep through methods requiring less time (e.g., the effects of sleeping eight hours are realized in four hours’ time) or enabling the SOF personnel to quickly reach and adequately cycle through the stages of sleep where the highest restorative effects occur (i.e., Stage 3/ deep sleep, and Stage 4/rapid eye movement sleep).

  • Optimal Acclimatization Strategies:
    The proposed project must research, apply, and/or develop novel approaches and/or technologies that provide rapid and sustainable human acclimatization in austere environments, to include fatigue countermeasure, extremes in temperature, extremes in altitude, and time-zone change (i.e., circadian acclimatization).

  • Wearables:
    The proposed project must research, apply, and/or develop novel approaches and/or wearable technologies, and/or leverage commercial-off-the-shelf wearable technologies that will monitor physiological measures of human performance to include, but not limited to, caloric expenditure, heart rate/heart rate response, heart rate variability, body fat percentage, sleep hygiene (deep and REM sleep duration) in real-time. Measures should be accurate with low fixed bias, wirelessly communicated via Bluetooth, Near Field Magnetic Induction or Radio Frequency technology in real-time and provide the command the capability to utilize the data for analysis of individuals and/or team performance via the USSOCOM Human Performance Data Management System. The device should be able to be turned on/off and/or have an inactive mode, provide real-time feedback on a display screen, be capable of displaying time, and be adjustable to fit users of different statures. Of parallel interest to address is a proposed project to track sleep, fatigue, and performance degradations through a wearable device that provides quantitative data (rather than qualitative surveys often seen in Fatigue Studies), that in turn will be gathered and amalgamated from entire units, in order to track individual performance, unit performance, mission impacts to performance levels, length of time for acclimatization (if it is ever achieved), and potential risk of mishaps.

  • Diagnostics for Performance Sustainment:
    The proposed project must research, apply, and/or develop minimally invasive diagnostic devices to provide actionable information on nutritional gaps, hormonal response to training, physiological response to performance interventions and recovery, and epigenetic predictors of potential injury.

  • Performance Nutrition:
    The proposed projects must research, apply and/or develop methods to accurately measure nutritional status of SOF personnel. The proposed project should focus on cost effectiveness, accuracy, and end-user compatibility (i.e., user friendly) methods or devices for identifying and optimizing an individual’s nutrient status. Consideration of alternative fuel (energy) sources, dietary supplementation, biomarkers, and nutrient volume/timing are specific areas of interest.

  • Physiological Performance:
    The proposed project must research, apply, and/or develop novel approaches and/or technologies to maximize the physiological performance of SOF personnel in austere and/or training environments, to include increased endurance, enhanced senses, tolerance to environmental extremes, and enhanced overall fitness, to maintain operational posture/ability in high stress scenarios without noticeable augmentation, and without hampering personnel mobility.

  • Cognitive Performance:
    The proposed project must research, apply, and/or develop novel approaches and/or technology that provide greater mental acuity or neuroenhancement (i.e., targeted enhancement and extension of cognitive and affective abilities). Encompasses pharmacological and non-pharmacological methods of improving cognitive, affective, motor functionality and performance, to include neuromodulation.

  • Psychological Performance and Suicide Prevention:
    The proposed project must research, apply, and/or develop novel approaches to the assessment and improvement of behavioral health within the force. Examples include but are not limited to, novel approaches to treatment and rehabilitation from acute and/or chronic post-traumatic stress, depression, and anxiety, improved emotional and nervous system self-regulation, digital/virtual engagement strategies, methods to measure behavioral health performance over time, and improved suicide prevention tools/strategies.

• Canine Medicine and Performance

  SOF personnel rely on canines’ exceptional capabilities as combat multipliers. This research area explores alternatives and/or new approaches to preserve and enhance SOF canine combat performance. SOF medical personnel place a premium on canine-specific approaches that are effective in extreme environments and do not require significant additional logistical support (i.e., maximize use of available SOF Medic materiel). The eight “Canine Medicine and Performance” project areas, to which SOF will give consideration, in priority order, are:

  • Trauma Resuscitation:

    The proposed project must support development of innovative techniques/strategies for canine trauma resuscitation (e.g., hypotensive resuscitation, whole blood/blood component replacement, and non-compressible hemorrhaging), particularly to address ballistic projectile injuries, in diverse/austere environments that lack immediately available medical evacuation or restorative surgical capacity.

    Note: Research should minimize or refrain from utilizing canine specific equipment or devices; this will allow treatment from existing trauma kits fielded by SOF Medics.

  • Non-Traditional Anesthesia Protocols:

    The proposed project must develop novel approaches for routine and emergency/post- traumatic canine field sedation and/or anesthesia in diverse environments and, utilizing pharmaceuticals available to SOF Medics.

  • Canine Performance:

    The proposed project must research, apply, and/or develop novel approaches and/or technologies that address optimization of canine performance through improved physical conditioning programs, reduction of cognitive decline, enhanced nutrition, and genetics research.

  • Sensory Optimization and Protection:

    Research must be oriented toward innovative methods that enhance or conserve SOF canine olfactory, visual, and/or auditory performance during combat operations.

  • Chemical, Biological, Radiological, Nuclear, and Explosive (CBRNE) Canine Decontamination, Treatment, and PPE Against Possible Exposure:

    The proposed projects must research, apply, and/or develop novel approaches that will diagnose, treat, decontaminate, and protect canines from exposure to chemical, biological, radiological, nuclear, and high yield explosives.

  • Environmental Extremes:

    Project proposals must research, apply, and/or develop novel strategies that address acclimatization to acute extremes in temperature, altitude, and/or time zone change (circadian acclimatization), and/or prolonged marine environmental exposure in SOF canines.

  • Brain Health and TBI

    Brain health research efforts include but are not limited to development and validation of NCATs, blast exposure and impact monitoring, determination of safe acceptable limits for blast exposure, validation of neurocognitive baseline testing, capabilities to easily determine mild, moderate, and severe TBI, pharmaceuticals to prevent or treat brain injury, validation of brain injury treatment strategies, and procedures to determine safe return to duty decisions for SOF canines.

  • Pre- and Post-Trauma Training / Behavioral Issues:

    The proposed project must address unique approaches to diagnosing and treating SOF-peculiar training and post-traumatic canine behavioral issues, to optimize pre-purchase selection and post-purchase training strategies across the enterprise and restore performance in canines with behavioral and/or post-trauma issues.

• Medical Sustainment

  SOF medical personnel require sustainment capabilities to support far-forward medical requirements to reduce the patient and supply risk associated with operational medicine. The proposed research, application, and/or development of medical sustainment techniques and materiel must address unique approaches to optimizing supply management and safeguarding equipment requirements. The project areas under “Medical Sustainment” to which the USSOCOM will give highest consideration are:

  • Power and Energy

    Project proposals must research, apply, and/or develop novel strategies that conserve or optimize medical equipment in-field use to reduce sustainment burden in prolonged, austere environments.

  • Austere Medical Logistics Procurement

    SOF personnel, operating in austere environments, may not have the ability to receive conventional resupply efforts. Project proposals must research, apply, and/or develop novel approaches to assist SOF personnel in developing and receiving medical resupplies or repair parts to meet their needs while in the field. These efforts must meet shipping and handling considerations (i.e. temperature control) for a wide range of medical products from batteries to blood. Efforts may include, but are not limited to, fabrication, improvisation, and/or delivery methods from sea, ground, air, or suborbital domains.

  • Equipment Protection

    Research that develops novel material and/or approaches to protect SOF medical equipment from environmental (i.e. CBRNE, freezing temperatures, etc.) and/or adversarial effects (i.e. jamming, electromagnetic pulse weapons, etc.).

  • Supply Monitoring Capability

    Project proposals must research, apply, and/or develop novel approaches to rapidly forecasting and calculating supply requirements based on patient treatment requirements, shelf-life, and storage considerations.

Are there any additional benefits I would receive?

Beyond direct funding, participation under the USSOCOM Biomedical and Human Performance BAA offers significant strategic advantages:

Government Validation and Credibility:
Being selected for funding by USSOCOM demonstrates exceptional technical capability and mission relevance to U.S. Special Operations Forces. This validation enhances your organization’s credibility with DoD program managers, defense primes, and dual-use technology investors seeking field-proven innovation.

Enhanced Market Visibility and Notoriety:
Awardees often gain visibility through federal award announcements, DoD communications, and defense medical research forums—positioning your company as a recognized contributor to national security and elite force readiness.

Ecosystem Access and Collaboration Opportunities:
Projects funded under this BAA operate within the broader military biomedical and human performance ecosystem, connecting recipients with military laboratories, medical R&D commands, and operational units. This access frequently leads to additional collaboration, follow-on funding, and contracting opportunities.

Stronger Exit and Acquisition Potential:
Advancing your technology with nondilutive government support and demonstrating validation in demanding SOF environments can significantly increase company valuation and strategic attractiveness for acquisition or investment by defense, medical, and performance technology leaders.

What is the timeline to apply and when would I receive funding?

• Open period: Continuously open through 31 July 2028.

• Two-step submission: Pre-proposal via eBRAP; if invited, submit the full application (generally within 60 days).

• Review & notice: Applicants should receive disposition within ~180 days of submission; awards may be made any time throughout the year and are contingent on funding and successful negotiations.

• Regulatory lead times: Allow 2–3 months for DoD human-subjects review (OHRO/HRPO) and 1–2 months for animal research review (VRO), as applicable.

Where does this funding come from?

Funding is provided by the Department of Defense (USSOCOM) and administered by the U.S. Army Medical Research Acquisition Activity (USAMRAA); the program leverages CDMRP/eBRAP systems. Any funds received by USSOCOM appropriate to the BAA’s research areas may be used, up to a program total of $20M annually.

Who is eligible to apply?

Organizations only: national/international, for-profit, non-profit, public, and private. FFRDCs are not eligible for direct awards but may team under their sponsoring agreements. Eligible investigators are individuals employed by/affiliated with eligible organizations. No cost sharing is required.

What companies and projects are likely to win?

Winning projects consistently score high on USSOCOM’s evaluation factors, which include:

• Technical Merit and Scientific Rigor: The proposed approach must be well-founded, methodologically sound, and clearly linked to measurable outcomes.

• Innovation and Impact: Reviewers favor projects that introduce novel methods, materials, or technologies capable of significantly improving SOF medical or performance capabilities. Incremental improvements without clear operational relevance tend to score poorly.

• SOF Relevance: Proposals must explicitly tie their work to unique SOF operational needs—such as portability, durability, limited logistics support, or extreme-environment applicability.

• Feasible Study Design and Realistic Execution Plan: Reviewers expect achievable milestones, well-defined deliverables, and credible transition pathways for eventual use by operational forces or integration into DoD systems.

• Qualified Team and Institutional Capability: Teams with demonstrated expertise in biomedical R&D, human performance, or defense health technology—and with access to appropriate facilities and regulatory infrastructure—are prioritized.

• Appropriate and Realistic Budget: Budgets should align with the scope and complexity of work, typically falling between $2 million and $10 million total costs for projects up to five years in duration.

Companies that combine strong technical innovation, credible execution capability, and a direct line of sight to SOF mission impact are most likely to be selected for funding.

Are there any restrictions I should know about?

• Project length: Up to 5 years.

• Pre-proposal required; unsolicited full proposals without invitation are rejected.

• Clinical trials are typically not associated with this BAA.

• Human/animal research approvals required.

• Administrative pitfalls leading to rejection/withdrawal include: missing/over-limit narratives, missing budget, inclusion of URLs in prohibited sections, and inconsistencies between pre-proposal and full application.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive pre-proposal will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

Our full service support is available for the pre-proposal for $7000. Full proposal quoted upon invitation.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

View the Funding Announcement: HT9425-23-S-SOC1 BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense

ARPA-H Scalable Solutions Office (SSO) BAA

Executive Summary:

ARPA-H’s Scalable Solutions Office (SSO) has an open “Mission Office Innovative Solutions Opening (ISO)” to fund revolutionary solutions that expand access, affordability, manufacturing, and distribution of health technologies across the U.S. healthcare system. The ISO accepts Solution Summaries and, if encouraged, full proposals; it anticipates multiple awards made as Other Transactions (OTs). The solicitation is open now and remains open until March 5, 2029.

How much funding would I receive?

The solicitation does not specify dollar amounts or funding ceilings. Awards are made as Other Transaction (OT) agreements at the government’s discretion, with specific payment structures negotiated individually. As a rule of thumb, companies should request only what they need to reach a meaningful technical or commercialization milestone—a concrete point that clearly demonstrates feasibility, enables transition, or unlocks follow-on investment.

What could I use the funding for?

This ISO seeks solution summaries and proposals for projects that fall within the general scope of the ARPA-H Scalable Solutions Office (SSO). The SSO seeks to improve health care access and affordability through revolutionary technical innovations that address the challenges of geography, distribution, manufacturing, and data- and information management. Many communities and remote areas in the United States lack access to timely and quality health care, which leads to disparities in health outcomes for those populations. Bottlenecks during the manufacturing processes of products and health technologies also lead to delays and limited availability, preventing effective distribution of health care solutions to areas of need, especially in emergencies.

Funded SSO health innovation projects will improve the readiness of technologies and medical capabilities to be rapidly, broadly, and affordably adopted by patients, providers, and payers throughout the healthcare ecosystem and improve the patient experience. Manufacturing and supply chain focused SSO projects will lower the bar to entry for new developers, accelerate the rate of development, reduce development and product costs, and improve reliability and agility in manufacturing and product distribution.

Solutions should focus on rapid innovation and the use of partnerships, as well as flexible distribution networks and streamlined manufacturing processes. The following SSO interest areas categorize the ground-breaking solutions we seek to support:

• Health Technologies and Interventions:

  • Approaches to improve affordability and access to health care that are adaptable to various geographic, demographic, economic contexts and can be rapidly and broadly deployed (e.g., drug-repurposing, point-of-care diagnostics, and modular health care infrastructure).

  • Tailored solutions that provide the pediatric population parity with the adult population with respect to access to treatments and other health care interventions, and that adapt to the pediatric patient’s changing physiology and developmental status over the course of years.

  • Transformational approaches to reduce or eliminate health disparities, including leap-ahead technologies that scale novel approaches in human factors, and human-centered design to respond to full diversity of patients in varied geographic settings. Tools to enable expansion of capacities, capabilities, and reach of individual and institutional healthcare providers (e.g., school nurses and schools, walk-in clinics, homesteading care) to address unmet health care access needs and expand availability of critical services.

  • Foundational capabilities to accelerate diagnoses of rare diseases and reduce the cost and increase the availability rare disease treatments wherever patients are, without the need for specialized facilities or healthcare expertise.

  • Novel materials and technologies to not only return autonomy to limited mobility and/or home bound patients.

• Advanced Technologies for Medical Product and Capability Distribution:

  • Methods for standardization, automation, and broad distribution of complex procedures including, but not limited to, histopathology, rare disease diagnosis and treatment, and surgical interventions to ensure access and delivery to all populations.

  • Technical approaches to enhance delivery of effective healthcare solutions, to include dentistry, in rural or low resource settings, including but not limited to "last mile delivery”, at-home monitoring and diagnosis, imaging, drug delivery, telehealth augmentation, and support for remote medical procedures with limited need for specialized training.

  • Technologies to enable the deployment of critical healthcare resources rapidly and securely at scale to the point of need in permissive and non-permissive (i.e., damaged infrastructure, cyberdenied) environments during a public health crisis or natural disaster.

  • Innovative information technology, data and analytic products and technologies to enable ordering, inventory management, situational awareness, allocation planning and demand forecasting of critical healthcare resources during a public health crisis or natural disaster.

• Biomanufacturing Innovations:

  • Innovative manufacturing technologies

    • Approaches that reduce costs; improve access; expedite production timelines; and strengthen domestic competitiveness for biologics, pharmaceuticals, medical devices and personalprotective equipment (PPE). These innovations aim to mitigate supply chain risks through:

      • Novel solutions to minimize the reliance on cold chain management and specialized handling of pharmaceuticals and biologics.

      • Scalable solutions to strengthen biomanufacturing supplychains, resolve bottlenecks, and enable domestic production, such as:

        • Improved production of active pharmaceutical ingredients, process consumables, and other critical materials (e.g., enzymes, cell lines, etc.).

        • Data-driven models to optimize bioprocessing, enhance process control, and bolster supply chain visibility.

        • Development of alternative materials and innovative methods for PPE manufacturing.

        • Improvement of capabilities to sustainably re-shore manufacturing and utilize readily accessible, cost-efficient feedstocks to strengthen the local and national industry bases.

  • Predictable, programable biological production

    • Advanced analytical technologies designed to improve product knowledge, accelerate release, and/or significantly improve analytical figures of merit.

    • Novel sensor systems, process analytical technologies, and associated process models to precisely manage bioproduction management, including:

      • Process control and monitoring systems.

      • Real-time release assays for rapid product validation.

      • Predictive capabilities to inform process development and enable efficient and effective scale-up of manufacturing to industrial scale.

Are there any additional benefits I would receive?

Beyond the formal funding award, there are significant indirect benefits to receiving an ARPA-H Scalable Solutions Office (SSO) agreement:

• Government Validation and Credibility:
  Being selected by ARPA-H—the nation’s newest high-impact biomedical research agency—signals exceptional scientific credibility and alignment with the federal government’s most forward-leaning health innovation priorities. This “ARPA-H validation” often accelerates partnerships with major healthcare systems, research institutions, and investors who recognize the rigor and selectivity of government-vetted innovation.

• Enhanced Market Visibility and Notoriety:
  Award recipients are frequently featured in ARPA-H announcements, federal health innovation communications, and national press coverage. This visibility positions your company as a recognized leader in translational health technology and attracts new collaborators, talent, and private-sector investment.

• Ecosystem Access and Collaboration Opportunities:
  ARPA-H performers gain access to a broad innovation ecosystem spanning federal health agencies, academic research centers, and industry partners. These relationships foster collaboration, facilitate regulatory readiness, and open pathways to follow-on contracts, pilot deployments, and commercialization opportunities within the U.S. health system.

• Nondilutive Growth and Strategic Leverage:
  Because funding is nondilutive, companies can scale and validate core technologies without giving up equity. This validation and maturity achieved under government sponsorship often lead to higher valuations and greater leverage in future fundraising or acquisition discussions.

What is the timeline to apply and when would I receive funding?

Open period: now through March 5, 2029.

• Step 1 (required): Submit a Solution Summary via the ARPA-H Solution Submission Portal. ARPA-H strives to provide written feedback within 30 business days of submission.

• Step 2: If encouraged, you’ll generally have 45 calendar days from feedback to submit a full proposal (unless ARPA-H specifies otherwise).

• Review cadence: ARPA-H reviews proposals on a rolling basis and strives to issue a decision within 60 calendar days of receiving a full proposal.

• Award timing: After selection, final negotiations for an Other Transaction (OT) award are completed rapidly, and invoicing is handled through Payment Management Services.

Because of this streamlined process, most ARPA-H applicants move from initial Solution Summary to award decision in approximately 4–5 months—making ARPA-H one of the fastest federal funders for high-impact health innovation projects.

Where does this funding come from?

The Advanced Research Projects Agency for Health (ARPA-H), a federal R&D agency within HHS, issuing awards under the authority of 42 U.S.C. § 290c(g)(1)(D) via OT agreements.

Who is eligible to apply?

Academia, non-profit organizations, for-profit entities, hospitals, community health centers, and non-federal research centers. Non-U.S. entities may participate if compliant with all applicable laws.

What companies and projects are likely to win?

Reviewers assess (in descending importance):

1. Scientific/technical merit—innovative, complete plans with clear deliverables, risks, and mitigations;

2. Contribution & relevance to ARPA-H’s mission—transformative potential, unmet need, commercialization/transition thinking, and IP/software approaches that enable adoption (preference for open standards/OSS where appropriate);

3. Team capabilities/experience—track record delivering similar efforts on budget/schedule;

4. Cost/budget alignment with the technical approach. ARPA-H encourages proposing the best technical solution over low-risk/minimal-uncertainty concepts.

Are there any restrictions I should know about?

• Standards & IP: strong preference for open, consensus-based standards (e.g., FHIR/TEFCA, DICOM) and commercial-friendly open-source licenses when feasible; proposals must justify any deviations/standard extensions and may need a pre-submission meeting for exceptions. Provide good-faith IP rights representations; pre-publication review may be required when sensitive info could be disclosed.

• Compliance: Human Subjects (IRB), Animal Subjects (IACUC), NIH Genomic Data Sharing (if applicable), CUI handling, research security disclosures (including CHIPS/NPSM-33 requirements), and OCI disclosures/mitigation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive full proposal under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 to submit a solution summary.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

ARPA-H Resilient Systems Office (RSO) BAA

Executive Summary:

ARPA-H’s Resilient Systems Office (RSO) is accepting innovative Solution Summaries and full proposals—on a rolling basis—aimed at strengthening the adaptability, reliability, and interoperability of the U.S. health ecosystem. Multiple awards are anticipated under flexible Other Transaction (OT) agreements. The ISO is open now and remains open until March 5, 2029.

How much funding would I receive?

The solicitation does not specify dollar amounts or funding ceilings. Awards are made as Other Transaction (OT) agreements at the government’s discretion, with specific payment structures negotiated individually. As a rule of thumb, companies should request only what they need to reach a meaningful technical or commercialization milestone—a concrete point that clearly demonstrates feasibility, enables transition, or unlocks follow-on investment.

What could I use the funding for?

The Resilient Systems Office (RSO), one of ARPA-H’s mission offices, seeks project proposals that drive innovations to enhance the adaptability, reliability, and interoperability of the health ecosystem. Submissions should aim for groundbreaking ideas that solve systemic challenges across the health landscape, leveraging cutting-edge technologies that address long-standing gaps in the quality, consistency, personalization, and efficacy of care.

RSO is interested in innovations that take a systems level approach in areas including, but not limited to, systems biology, data systems, biophysical systems, health IT systems, sociotechnical systems, health-related systems engineering, and other systems with the potential to improve health outcomes. While RSO welcomes “out of the box” ideas to address the above gaps, the mission office encourages proposals that address the following areas:

• Fortifying systems to improve robustness:

  Novel system designs and modular capabilities that extend the shelf-life of systems, ensuring peak performance across a broad range of healthcare environments and use cases. Applications of interest include, but are not limited to, the adaptability and robustness of biological systems; digital platforms for secure and efficient management of information; and socio-technical systems to maintain access to care and critical information.

• Removing barriers to enhance system efficiency and efficacy:

  Approaches that provide paradigm shifts in system dynamics to improve health outcomes. This includes improvements to system interoperability, process, and transparency; foundational capabilities to enable integration of emerging technology solutions; overcoming systemic barriers driven by misaligned incentives; user-centric tools that improve patient care coordination and user experience; and clinical and research solutions to boost efficiency, reduce cognitive load, and accelerate scientific discovery and its application.

• Early detection and interventions to mitigate disruptions to the healthcare ecosystem:

  Agile interventions to reduce the impact of disruptions and enhance readiness to manage and recover from large-scale health events. This spans the entire health system, including supply chains, manufacturing, and logistics.

Are there any additional benefits I would receive?

Beyond the formal funding award, there are significant indirect benefits to receiving an ARPA-H Resilient Systems Office (RSO) agreement:

• Government Validation and Credibility:
  Being selected by ARPA-H—the nation’s newest high-impact biomedical research agency—signals exceptional scientific credibility and alignment with the federal government’s most forward-leaning health innovation priorities. This “ARPA-H validation” often accelerates partnerships with major healthcare systems, research institutions, and investors who recognize the rigor and selectivity of government-vetted innovation.

• Enhanced Market Visibility and Notoriety:
  Award recipients are frequently featured in ARPA-H announcements, federal health innovation communications, and national press coverage. This visibility positions your company as a recognized leader in translational health technology and attracts new collaborators, talent, and private-sector investment.

• Ecosystem Access and Collaboration Opportunities:
  ARPA-H performers gain access to a broad innovation ecosystem spanning federal health agencies, academic research centers, and industry partners. These relationships foster collaboration, facilitate regulatory readiness, and open pathways to follow-on contracts, pilot deployments, and commercialization opportunities within the U.S. health system.

• Nondilutive Growth and Strategic Leverage:
  Because funding is nondilutive, companies can scale and validate core technologies without giving up equity. This validation and maturity achieved under government sponsorship often lead to higher valuations and greater leverage in future fundraising or acquisition discussions.

What is the timeline to apply and when would I receive funding?

Open period: now through March 5, 2029.

• Step 1 (required): Submit a Solution Summary via the ARPA-H Solution Submission Portal. ARPA-H strives to provide written feedback within 30 business days of submission.

• Step 2: If encouraged, you’ll generally have 45 calendar days from feedback to submit a full proposal (unless ARPA-H specifies otherwise).

• Review cadence: ARPA-H reviews proposals on a rolling basis and strives to issue a decision within 60 calendar days of receiving a full proposal.

• Award timing: After selection, final negotiations for an Other Transaction (OT) award are completed rapidly, and invoicing is handled through Payment Management Services.

Because of this streamlined process, most ARPA-H applicants move from initial Solution Summary to award decision in approximately 4–5 months—making ARPA-H one of the fastest federal funders for high-impact health innovation projects.

Where does this funding come from?

The Advanced Research Projects Agency for Health (ARPA-H), a federal R&D agency within HHS, issuing awards under the authority of 42 U.S.C. § 290c(g)(1)(D) via OT agreements.

Who is eligible to apply?

Academia, non-profit organizations, for-profit entities, hospitals, community health centers, and non-federal research centers. Non-U.S. entities may participate if compliant with all applicable laws.

What companies and projects are likely to win?

Reviewers assess (in descending importance):

1. Scientific/technical merit—innovative, complete plans with clear deliverables, risks, and mitigations;

2. Contribution & relevance to ARPA-H’s mission—transformative potential, unmet need, commercialization/transition thinking, and IP/software approaches that enable adoption (preference for open standards/OSS where appropriate);

3. Team capabilities/experience—track record delivering similar efforts on budget/schedule;

4. Cost/budget alignment with the technical approach. ARPA-H encourages proposing the best technical solution over low-risk/minimal-uncertainty concepts.

Are there any restrictions I should know about?

• Standards & IP: strong preference for open, consensus-based standards (e.g., FHIR/TEFCA, DICOM) and commercial-friendly open-source licenses when feasible; proposals must justify any deviations/standard extensions and may need a pre-submission meeting for exceptions. Provide good-faith IP rights representations; pre-publication review may be required when sensitive info could be disclosed.

• Compliance: Human Subjects (IRB), Animal Subjects (IACUC), NIH Genomic Data Sharing (if applicable), CUI handling, research security disclosures (including CHIPS/NPSM-33 requirements), and OCI disclosures/mitigation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive full proposal under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 to submit a solution summary.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

ARPA-H Proactive Health Office (PHO) BAA

Executive Summary:

ARPA-H’s Proactive Health Office (PHO) has an open Innovative Solutions Opening (ISO) to fund high-impact R&D that improves health span and health outcomes before disease onset. The ISO accepts Solution Summaries now through March 5, 2029, with multiple awards anticipated under Other Transactions (OTs). Eligible proposers include for-profit companies, non-profits, and academia. Solutions must be novel (not incremental) and align with PHO interests in prevention, early detection, behavior change, and system-level innovations.

How much funding would I receive?

The solicitation does not specify dollar amounts or funding ceilings. Awards are made as Other Transaction (OT) agreements at the government’s discretion, with specific payment structures negotiated individually. As a rule of thumb, companies should request only what they need to reach a meaningful technical or commercialization milestone—a concrete point that clearly demonstrates feasibility, enables transition, or unlocks follow-on investment.

What could I use the funding for?

The Proactive Health Office (PHO), one of ARPA-H’s mission offices, is seeking solutions to improve the health spans and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Specifically, PHO hypothesizes that: 1) the development of novel early detection methods and prophylactic interventions could drastically improve the health of American throughout their lives; 2) population-level improvements in access to and uptake of disease increase prevention- and wellness-promoting behaviors; and 3) system-level innovations are required to deliver proactive health measures effectively.

Specific PHO interest areas include:

• Novel prevention, detection, and prophylactic treatment methods for disease, including:

  i. Prophylactic approaches to prevention of diseases and harmfuldisease outcomes.

  ii. Methods for continuous and widespread sensing of health-state, and early disease indicators that can be deployed at population-scales.

  iii. Novel and scalable methods for early detection of disease and illness that include the use of low/no-cost sensing modalities.

• Population-level approaches to increase the adoption of prevention- and wellness behaviors:

  i. Methods to inform and educate individuals about healthy behaviors, including lifestyle and preventative medical measures.

  ii. Methods that incentivize individuals to adopt and maintain healthy behaviors.

  iii. Novel approaches to increasing individual health spans and independence even in the absence of disease.

  iv. Early indicators of both disease- and pre-disease states, and measures associated with proactive health outcomes that are both inexpensive and effective. Low-cost, high-uptake mental health resiliency and mindfulness-building methods for individuals.

• System innovation for the delivery of proactive health outcomes:

  i. Novel, robust, and predictive surrogates for long-term health outcomes with associated epidemiological models.

  ii. Valuation models for long-term treatment effects for vaccination, screening, and other public health interventions.

  iii. New funding and delivery models for preventative interventions.

• Other Topics

  High-quality submissions that propose revolutionary technologies that meet the goals of PHO will be considered even if they do not address the areas of interest listed above.

Are there any additional benefits I would receive?

Beyond the formal funding award, there are significant indirect benefits to receiving an ARPA-H Proactive Health Office (PHO) agreement:

• Government Validation and Credibility:
  Being selected by ARPA-H—the nation’s newest high-impact biomedical research agency—signals exceptional scientific credibility and alignment with the federal government’s most forward-leaning health innovation priorities. This “ARPA-H validation” often accelerates partnerships with major healthcare systems, research institutions, and investors who recognize the rigor and selectivity of government-vetted innovation.

• Enhanced Market Visibility and Notoriety:
  Award recipients are frequently featured in ARPA-H announcements, federal health innovation communications, and national press coverage. This visibility positions your company as a recognized leader in translational health technology and attracts new collaborators, talent, and private-sector investment.

• Ecosystem Access and Collaboration Opportunities:
  ARPA-H performers gain access to a broad innovation ecosystem spanning federal health agencies, academic research centers, and industry partners. These relationships foster collaboration, facilitate regulatory readiness, and open pathways to follow-on contracts, pilot deployments, and commercialization opportunities within the U.S. health system.

• Nondilutive Growth and Strategic Leverage:
  Because funding is nondilutive, companies can scale and validate core technologies without giving up equity. This validation and maturity achieved under government sponsorship often lead to higher valuations and greater leverage in future fundraising or acquisition discussions.

What is the timeline to apply and when would I receive funding?

Open period: now through March 5, 2029.

• Step 1 (required): Submit a Solution Summary via the ARPA-H Solution Submission Portal. ARPA-H strives to provide written feedback within 30 business days of submission.

• Step 2: If encouraged, you’ll generally have 45 calendar days from feedback to submit a full proposal (unless ARPA-H specifies otherwise).

• Review cadence: ARPA-H reviews proposals on a rolling basis and strives to issue a decision within 60 calendar days of receiving a full proposal.

• Award timing: After selection, final negotiations for an Other Transaction (OT) award are completed rapidly, and invoicing is handled through Payment Management Services.

Because of this streamlined process, most ARPA-H applicants move from initial Solution Summary to award decision in approximately 4–5 months—making ARPA-H one of the fastest federal funders for high-impact health innovation projects.

Where does this funding come from?

The Advanced Research Projects Agency for Health (ARPA-H), a federal R&D agency within HHS, issuing awards under the authority of 42 U.S.C. § 290c(g)(1)(D) via OT agreements.

Who is eligible to apply?

Academia, non-profit organizations, for-profit entities, hospitals, community health centers, and non-federal research centers. Non-U.S. entities may participate if compliant with all applicable laws.

What companies and projects are likely to win?

Reviewers assess (in descending importance):

1. Scientific/technical merit—innovative, complete plans with clear deliverables, risks, and mitigations;

2. Contribution & relevance to ARPA-H’s mission—transformative potential, unmet need, commercialization/transition thinking, and IP/software approaches that enable adoption (preference for open standards/OSS where appropriate);

3. Team capabilities/experience—track record delivering similar efforts on budget/schedule;

4. Cost/budget alignment with the technical approach. ARPA-H encourages proposing the best technical solution over low-risk/minimal-uncertainty concepts.

Are there any restrictions I should know about?

• Standards & IP: strong preference for open, consensus-based standards (e.g., FHIR/TEFCA, DICOM) and commercial-friendly open-source licenses when feasible; proposals must justify any deviations/standard extensions and may need a pre-submission meeting for exceptions. Provide good-faith IP rights representations; pre-publication review may be required when sensitive info could be disclosed.

• Compliance: Human Subjects (IRB), Animal Subjects (IACUC), NIH Genomic Data Sharing (if applicable), CUI handling, research security disclosures (including CHIPS/NPSM-33 requirements), and OCI disclosures/mitigation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive full proposal under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 to submit a solution summary.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

ARPA-H Health Science Futures (HSF) Mission Office BAA

Executive Summary:

The ARPA-H Health Science Futures (HSF) Mission Office is accepting Solution Summaries and full proposals for revolutionary health R&D under its Innovative Solutions Opening (ISO), ARPA-H-SOL-24-104. Multiple awards are anticipated via Other Transaction (OT) agreements. The ISO remains open through March 5, 2029, and you must submit a short Solution Summary and receive written feedback before a full proposal. Submissions must align with HSF focus areas (e.g., breakthrough technologies, transformative tools, and adaptable platform systems) and are expected to be high-risk, high-impact—incremental or clinical-trial-stage efforts are out of scope.

How much funding would I receive?

The solicitation does not specify dollar amounts or funding ceilings. Awards are made as Other Transaction (OT) agreements at the government’s discretion, with specific payment structures negotiated individually. As a rule of thumb, companies should request only what they need to reach a meaningful technical or commercialization milestone—a concrete point that clearly demonstrates feasibility, enables transition, or unlocks follow-on investment.

What could I use the funding for?

This ISO seeks solution summaries and proposal submissions for projects that fall within the general scope of the ARPA-H Health Science Futures (HSF) mission office. The HSF mission office expands what is technically possible by developing approaches that will remove the scientific and technological limitations that stymie progress towards the healthcare of the future. The HSF mission office
supports cutting-edge, often disease-agnostic research programs that have the potential for translational real-world change. Specifically excluded from consideration are proposals that represent an evolutionary or incremental advance in the current state of the art, or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed toward policy changes; traditional education and training; center coordination, formation, or development; and construction of physical infrastructure are outside the scope of the ARPA-H mission.

The following areas define the ground-breaking research that HSF seeks to support:

• Breakthrough Technologies

  Paradigm shifting technologies that will change how we approach the diagnosis, treatment, and impact of diseases and conditions.

  • Novel approaches to improve maternal and fetal medicine, decrease maternal morbidity and mortality during birth, and the post-partum period. Efforts should include new technology to monitor, detect, and/or treat maternal and/or fetal complications with less invasive and traumatic methods.

  • Foundational advances in genetic, epigenetic, cellular, tissue, and organ replacement therapies that enable personalized medical interventions at scale in a manner that is accessible, cost-effective, and designed to impact the communities of greatest need.

  • Interventions that target and reverse disease pathogenesis and/or enhance plasticity to address diseases of the nervous, neuromuscular, skeletal, lymphatic, cardiovascular, and other organ systems.

  • Novel approaches to definitively diagnose and cure chronic diseases including, but not limited to, diabetes, autoimmune diseases, neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease, ALS, etc.), and cancer.

  • Technologies that expand the precision, scale, and accessibility of brain circuit mapping technologies that enable causative neuropsychiatric links to mental health disorders leading to definitive diagnosis and reliable therapeutic monitoring.

• Transformative Tools

  Novel, agile solutions that will move from bench to bedside quickly, facilitating revolutionary advances in medical care.

  • Development of tools that counter idiosyncratic, off-target, or chronic effects of medicines that are commonly used or that are being used experimentally to treat or prevent disease.

  • Development of bionic or biohybrid devices that enable direct integration and communication with the body to activate restorative pathways that restore lost senses, physical abilities, immune functions, and other organ functions.

  • Site-selective neuromodulation to regulate specific physiological functions and treat chronic health conditions such as inflammation, pain, and metabolic or endocrine disorders.

  • Synthetic biology approaches incorporating novel logic mechanisms, disease targeting and response methods, and robust control strategies to diagnose, and/or cure a multitude of diseases.

  • Imaging or other technologies engineered from discoveries at the forefront of physics and/or chemistry that reduce cost, improve size and/or portability, increase availability, expand capability, improve resolution, reduce exposure to radiation, and accommodate pediatric patient populations.

  • Integrated sensing and therapy delivery devices for addressing chronic health conditions, including mental health conditions or substance use disorders.

• Platform Systems

  Adaptable, multi-application systems and technologies that are reconfigurable for a wide variety of clinical needs.

  • Novel molecular platforms to target and cure diseases, including the modulation of physiological systems, delivery to targets with spatial and temporal precision, and mitigation of off-target effects to accelerate interventions that dramatically improve health outcomes.

  • New approaches to accelerate and routinize mammalian and microbial cellular engineering to enable next generation therapeutic applications, develop multiscale interventions, and automate hypothesis generation and discovery to expand those applications to disease states in which cellular therapies have not traditionally been employed.

  • Innovative approaches at the intersection of artificial intelligence, high performance computing (including quantum computing) and biological systems, including enabling de novo design of biomolecules with entirely new phenotypes.

  • Revolutionary omics platforms that enable unprecedented spatial and temporal scales and resolution of physiological and disease mechanisms.

• Other Technologies

  Other high-quality submissions that propose revolutionary technologies that meet the goals of HSF will be considered even if they do not address the other listed topics.

  Proposals in response to this Innovative Solutions Opening (ISO) are expected to identify innovative approaches to enable revolutionary advances in medicine and healthcare and the science and technologies underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that offer radically new insights to address specific health conditions, including (but not limited to) cancer, cardiovascular, diabetes, infectious and neurological diseases, and pediatric and maternal/fetal health.

Are there any additional benefits I would receive?

Beyond the formal funding award, there are significant indirect benefits to receiving an ARPA-H Health Science Futures (HSF) agreement:

• Government Validation and Credibility:
  Being selected by ARPA-H—the nation’s newest high-impact biomedical research agency—signals exceptional scientific credibility and alignment with the federal government’s most forward-leaning health innovation priorities. This “ARPA-H validation” often accelerates partnerships with major healthcare systems, research institutions, and investors who recognize the rigor and selectivity of government-vetted innovation.

• Enhanced Market Visibility and Notoriety:
  Award recipients are frequently featured in ARPA-H announcements, federal health innovation communications, and national press coverage. This visibility positions your company as a recognized leader in translational health technology and attracts new collaborators, talent, and private-sector investment.

• Ecosystem Access and Collaboration Opportunities:
  ARPA-H performers gain access to a broad innovation ecosystem spanning federal health agencies, academic research centers, and industry partners. These relationships foster collaboration, facilitate regulatory readiness, and open pathways to follow-on contracts, pilot deployments, and commercialization opportunities within the U.S. health system.

• Nondilutive Growth and Strategic Leverage:
  Because funding is nondilutive, companies can scale and validate core technologies without giving up equity. This validation and maturity achieved under government sponsorship often lead to higher valuations and greater leverage in future fundraising or acquisition discussions.

What is the timeline to apply and when would I receive funding?

Open period: now through March 5, 2029.

• Step 1 (required): Submit a Solution Summary via the ARPA-H Solution Submission Portal. ARPA-H strives to provide written feedback within 30 business days of submission.

• Step 2: If encouraged, you’ll generally have 45 calendar days from feedback to submit a full proposal (unless ARPA-H specifies otherwise).

• Review cadence: ARPA-H reviews proposals on a rolling basis and strives to issue a decision within 60 calendar days of receiving a full proposal.

• Award timing: After selection, final negotiations for an Other Transaction (OT) award are completed rapidly, and invoicing is handled through Payment Management Services.

Because of this streamlined process, most ARPA-H applicants move from initial Solution Summary to award decision in approximately 4–5 months—making ARPA-H one of the fastest federal funders for high-impact health innovation projects.

Where does this funding come from?

The Advanced Research Projects Agency for Health (ARPA-H), a federal R&D agency within HHS, issuing awards under the authority of 42 U.S.C. § 290c(g)(1)(D) via OT agreements.

Who is eligible to apply?

Academia, non-profit organizations, for-profit entities, hospitals, community health centers, and non-federal research centers. Non-U.S. entities may participate if compliant with all applicable laws.

What companies and projects are likely to win?

Reviewers assess (in descending importance):

1. Scientific/technical merit—innovative, complete plans with clear deliverables, risks, and mitigations;

2. Contribution & relevance to ARPA-H’s mission—transformative potential, unmet need, commercialization/transition thinking, and IP/software approaches that enable adoption (preference for open standards/OSS where appropriate);

3. Team capabilities/experience—track record delivering similar efforts on budget/schedule;

4. Cost/budget alignment with the technical approach. ARPA-H encourages proposing the best technical solution over low-risk/minimal-uncertainty concepts.

Are there any restrictions I should know about?

• Standards & IP: strong preference for open, consensus-based standards (e.g., FHIR/TEFCA, DICOM) and commercial-friendly open-source licenses when feasible; proposals must justify any deviations/standard extensions and may need a pre-submission meeting for exceptions. Provide good-faith IP rights representations; pre-publication review may be required when sensitive info could be disclosed.

• Compliance: Human Subjects (IRB), Animal Subjects (IACUC), NIH Genomic Data Sharing (if applicable), CUI handling, research security disclosures (including CHIPS/NPSM-33 requirements), and OCI disclosures/mitigation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive full proposal under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 to submit a solution summary.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Continuing Enabling, Enhancing, Restoring and Sustaining (CHEERS) Multiple Authority Announcement (MAA)

Executive Summary:

The Air Force Research Laboratory’s Human Effectiveness Directorate (AFRL/RH) and the U.S. Air Force School of Aerospace Medicine (USAFSAM) are awarding up to $1 billion in total funding under the CHEERS Multiple Authority Announcement (MAA) to support U.S. companies, universities, and research partners advancing technologies that enhance human performance, resilience, and health in aerospace and defense environments.

White papers are accepted through September 30, 2027, and proposal invitations are issued on a rolling basis. Companies should submit white papers as soon as possible in order to have the highest likelihood of funding.

How much funding would I receive?

Funding is project-dependent and determined by the technical approach propose. Typical awards will range from $300,000 to $5,000,000.

What could I use the funding for?

Funding can used for the full range of R&D activities from basic and applied R&D to prototype and experimental testing. See a list of focus areas below:

• Airman Systems Directorate (RH)

  Activities within the 711HPW are organized into research areas which are categorized based on the technology readiness level (TRL). Product lines focus on advanced technology development and identifying paths for technology transition while the CTC’s and CRA’s focus on basic research through early applied research. Each division further breaks down the research into Lines of Effort (LoE) or Product Area (PA) for each CTC or PL, respectively. Descriptors of PL, CTC and CRA are provided below:

  • Product Line (PL): An organizational construct within the Airman Systems Directorate for engineering and transition of technology to the Department of the Air Force and Department of Defense. A Product Line organizes and manages inter-related technology demonstrations and transition paths for Airman Systems Directorate technologies at late applied and advanced technology development stages. The product line may integrate research and engineering tasks across several CTCs within AFRL.

  • Core Technical Competency (CTC): CTCs represent the technical foundation that is difficult to duplicate and allows AFRL to provide unique technical leadership. They span basic research, applied research, and advanced technology development encompassing the people, information, facilities, equipment, and programs allowing AFRL to solve critical AF and national security problems.

  • Core Research Area (CRA): A subset of the Core Technical Competencies within the Airman Systems Directorate. CRAs represent a focused group of basic and early applied research, focused on investigating revolutionary, higher risk concepts. The CRAs mature new foundational technologies and transition promising research to product lines of the organization.

  Airman Biosciences (RHB)

  • Aerospace & Operational Medicine PL1: Matures and transitions aeromedical knowledge, technology, and materiel solutions in force health protection, human health and performance, and aeromedical evacuation & enroute care in order to enable, sustain, enhance, and restore operational and aeromedical health and human performance for Airmen executing Air Force missions across all operational domains. Objectives focus on generating high performance Airmen and Guardians through medical availability, enhancing joint combatant commander capabilities, and maximizing human capital and strategic resources by aligning resources to strategic and workforce development. The goal is to transition products that address validated AF/AFMS requirements by focusing on stakeholder engagement to ensure clear demand signals and to create and maintain extensive partnership network to ensure rapid execution and flexibility.

    • Air & Space Austere Environment Patient Transport (En Route Care) PA1: Advances combat casualty care in the air through biomedical research into interventional strategies and technologies that mitigate the risks for additional insult due to aeromedical evacuation. Transitions promising Science and Technology (S&T) into knowledge and material products that promote the recovery and return to duty of injured or ill service members, from point of injury back to definitive care. Research within this program includes but is not limited to ground medical operations in agile combat employment, autonomous care of patient movement, and optimization of patient movement.

    • Air & Space Force Health Protection (FHP) PA2: Medical development and biomedical technology investments seek to deliver an improved FHP capability across the full spectrum of operations with research that prevents injury/ illness through improved identification and control of health risks. Under FHP, subproject areas include Occupational Hazard Exposure (Includes Flight Hazards and Integrated Risk), Targeted Risk Identification, Mitigation and Treatment (Formerly Pathogen ID and Novel Therapeutics and includes Big Data), FHP Technologies Development and Assessment (Assay and disease detection), and Health Surveillance, Infection, Injury & Immunity. FHP also includes Innovations and Personalized Medicine. Operational medicine is focused on in garrison care – our next most critical issue post OIF/OEF – and how to care for the whole patient and consideration of comorbidities in treatment of wounded warriors and dependents.

  • Biotechnology for Performance, Research, and Demonstration PL2: Develops and delivers capabilities to enhance human performance in near-peer conflict. Objectives focus on modular systems that integrate with warfighting platforms and maintaining and enhancing end-user engagement to ensure relevance and realism all while working in close sync with DoD and external partners to deliver high value solutions. The goal is to build momentum for Wearable technology, continue to develop and advocate for human assessment & tracking, strategically plan for product usage in austere environments, and expand on current platform products to develop and connect capabilities with operational challenges.

    • Airman Sensing & Assessment PA1: Develop and demonstrate advanced prototype products that integrate physiological, cognitive, behavioral, and environmental sensing capabilities with validated analytics, assessments, and intervention capabilities to sustain and enhance air and space operator performance.

    • Human Performance Augmentation & Development PA2: Develop and deliver capabilities to enhance human performance in near-peer conflict by focusing on modular systems that integrate with warfighting platforms. Working in close sync with DoD and external partners to deliver high value solutions to maintain and enhance end-user engagement to ensure relevance and realism.

    • Air & Space Physiology, Medicine, and Human Performance (HP) PA3: Enables, sustains, and optimizes performance of Airmen through elevation and alleviation of health effects associated with AF operational missions. Addresses operational environments such as the mitigation of stress in AF personnel, to include aircrew, care providers, aircraft maintainers, intelligence, surveillance and cyber operators, as well as remote piloted aircraft operators. Research within this project includes but is not limited to airman performance and readiness, advancing air and space medicine, and medical operator performance digital engineering. Advanced technology development to enable, sustain, and optimize cognitive, behavior and physiologic performance in highpriority career fields for the United States Air Force (USAF) and in multidomain operations. The sub-project areas include cognitive and physiologic performance under operational and environmental stressors, detection and improvement of physiological performance, and safety via sensor systems and targeted conditioning, which includes training techniques for optimal performance. This project also develops and demonstrates technologies which ingest health status monitoring data to provide scalable situational awareness of individual, unit, and group medical readiness in support of command and control and develops strategies to mitigate performance limitations through physical, pharmacological/non-pharmacological, or behavioral medical interventions and/or technological augmentation.

  • Medical and Operational Biosciences CTC1: Develops, validates, and enhances medical and operational biosciences and emergent biotechnologies for transition into advanced development products in the Air and Space operational environment to lead to a highly resilient and medically ready force. These products can sense, assess, sustain, and segment warfighter physiological-cognitive performance in multi-domain operations. Deliverables will be enhancing and researching new technologies and concepts to sustain, augment, and restore the multi-domain Airman & Guardian Health and Performance. Customers, end-users, and stakeholders include the DHP and DAF 6.3 programs and product lines: Human Performance/Medical Readiness, Force Health Protection, and En Route Care as some of the primary users.

    • Biotechnology for Health and Performance CRA1: The Biotechnology for Health and Performance CRA utilizes multivariant, systems biology approaches to provide advanced science and technology solutions to understand the warfighter’s biologic state and the underlying mechanism of responses with the goal of enabling, enhancing, and sustaining the human's ability to dominate air, space and cyberspace.

    • Applied Cognitive Neurosciences CRA2: Develops and validates technologies in cognitive neuroscience and physical performance to sustain, augment, and recover operator performance and determine medical attributes/metrics for optimal career field alignment.

    • Health and Performance Sensing and Assessment CRA3: Develops sensing technologies in a variety of form factors to identify, validate and monitor human signatures related to Airmen's and Guardians’ health, exposures and physical/cognitive performance in their associated environments. The research from this CRA will develop sensing solutions optimized for real-time, noninvasive and autonomous sensing and assessing capabilities to enhance and protect Airmen and Guardians in a variety of operational environments.

    • Biomedical Impact of Air and Space CRA4: Conducts research investigating Airman and Guardian performance degradation resulting from exposure to air and space environments and seek understanding the fundamental mechanisms driving environmental and operational risks. Develop technologies to mitigate or eliminate the root physiologic causes of these degradations and to ultimately optimize Airman and Guardian performance resulting in the capability to fly faster, higher, and longer than our adversaries.

  Bioeffects (RHD)

  • Bioeffects PL: Creates and demonstrates developmental technology & tools to generate products/applications. These products provide optimized design requirements for weapon systems & personal protection device developers, risk and collateral hazard assessments for directed energy systems, and analysis libraries for the representation of humans as part of model-based systems engineering approaches and within engineering-level models of system performance, informing overall system performance impacts and adding fidelity to concepts in wargames. Approaches include the integration of components in engagement and mission-level simulation tools within USAF and DoD software architectures, and model-based systems engineering artifacts to enable future integration and technology transition. Key technologies include directed energy bioeffects systems characterization and risk assessment, directed energy bioeffects components of modeling and simulation tools, and human representation in digital engineering.

  • Bioeffects CTC1: The Bioeffects CTC will conduct research to enable the maximum safe exploitation of the electromagnetic spectrum for nation defense by protecting personnel & communities and assessing weapons applications. CTC research will focus on characterizing fundamental bioeffects, optimizing the safety/effectiveness of directed Energy systems, developing/assessing dosimetry tools, modeling & simulation of products/applications, protecting device development and providing science-based information to national & international safety standards.

    • Directed Energy Bioeffects Modeling, Simulation, & Analysis CRA1: The directed energy bioeffects modeling, simulation, & analysis core research area emphasizes research that focuses on new modeling, simulation, and analysis techniques which represent and optimize concepts of directed energy systems employment from the bioeffect standpoint, develops capabilities for studies and means of measuring of effectiveness and suitability for directed energy systems to include direct, scalable, and collateral effects. Research areas include highperformance/ high-fidelity multi-physics simulations, advanced electromagnetic dosimetry models, mechanistic theories & models of injury, thermal/thermoregulatory response models, physics-to-physiology color vision theory, component models of human response to directed energy, statistical approaches for risk assessment, near-real-time numerical approaches and surrogating complexity through machine learning.

      • Directed Energy Bioeffects Modeling Simulation & Analysis LOE1: Develop and mature physics & engineering-level models for directed energy dosimetry & the resulting biological effects; create algorithms encapsulating empirical datasets & physics-level models of directed energy dose response; supports directed energy modernization campaign and enables the Directed Energy Weapons Review and Approval (DEWRAP) process.

      • Directed Energy Bioeffects Dosimetry LOE3: Develop novel dosimetry to better understand directed energy interactions and injury to inform software approaches enabling simulation of dynamic scenarios; supports directed energy modernization.

    • Directed Energy Bioeffects & Mechanisms CRA2: The directed energy bioeffects & mechanisms CRA provides fundamental knowledge of mechanisms of interaction of directed energy with molecules, cells, tissues, and organs in support of military directed energy systems and enables future weapon systems with scalable, disruptive, and ultra-precise effects. Research areas include: discovery science for understanding mechanisms, neurobiological & behavioral response to directed energy, hardening of biological targets to directed energy, mechanistic response of human vision to directed energy, epigenetic response to directed energy exposure, membrane and ion channel response to rapid onset exposures, supra-threshold response – severity of effects, and human factors in technologies for protection.

      • Research in Directed Energy Multi-Interaction Systems LOE2: Develop and deliver an integrated modeling environment and studies to address critical national defense interests & prevent technological surprises. Study radio frequency, combined or synergistic responses, and their interaction with biology.

      • Directed Energy Hazard & Protection Assessment LOE4: Feedback & expertise for DoD to optimize safety/performance trades for directed energy systems; evaluation of dose-response of directed energy exposures to achieve specific endpoint; understand human vision response to optical radiation and related protective devices; elucidate margin of effectiveness and safety to meet DoD mission success. Assure no technology surprise.

      • Directed Energy Weapon Effects LOE5: Feedback & expertise for DoD to optimize safety/performance trades for directed energy systems & provide scientific basis for risk criteria definitions; Allows directed energy weapon modernization & enables review and approval processes for weapons systems.

  Warfighter Interactions & Readiness (RHW)

  • Airman-Machine Integration PL1: Delivers advanced, situationally-adaptive and scalable interface technologies and decision aiding tools. S&T is focused on ABMS compliant, intuitive user interfaces, and intelligent aided decision support to provide rapid, accurate battlefield awareness, maximized distributed human-machine team performance and decision superiority. Operator-centric interfaces increase human combat capabilities while managing human cognitive workload in complex, degraded environments. Key technologies include human-autonomy collaboration and trust in autonomy, development of successful distributed, heterogeneous teams with metrics of team performance, exploitation of human perception and enhancement of operational communication. These efforts address the critical needs for ABMS and JADC2 with optimal human-machine teams ready to operate.

  • Readiness PL2: Develops and extends technologies and tools for improving the cognitive effectiveness, performance and proficiency of airmen in current and potential future operational mission contexts. Aims to deliver operationally relevant, unobtrusive, integrated metrics, software, & hardware to assess proficiency & readiness in real-time. Develops methodologies to create models & algorithms for performance prediction, training support, & automated instruction. Key technologies include the ability to support multi-capable airmen resilience and mission performance in austere deployed contexts and develop standards for sharable scenario content, data, models, & metrics.

  • Analytics PL3: Identifies & matures software that streamlines workflow & enables cognition at the scale of war, enabling airmen effectiveness in the air, space, & cyberspace domains for effective C2ISR in Multi-Domain Operations. Develops analytic tools that optimize human cognition with the power of machine computation, thereby enabling consumers to better visualize, interpret, and act on information. Aims to deliver software that is open-architecture, modular, networked, and distributed; able to leverage statistics, machine learning, and artificial intelligence; and focuses on speed, accuracy, insight, and action.

  • Warfighter Interfaces and Teaming CTC1: The Warfighter Interfaces and Teaming CTC will conduct research to enable robust decision superiority across our Air and Space Forces by dynamically optimizing the integration of Warfighter cognition with increasingly complex and intelligent machines/systems, creating maximally effective and resilient warfighting teams. CTC research will focus on discovering, developing, evaluating, and transitioning advanced adaptive warfighter interface technology, mission-optimized distributed team performance enhancements, communication management processes, and context-tailored intelligent decision aids/analytics in order to achieve and maintain decision superiority in uncertain environments against peer threats.

    • Distributed Teaming and Communication CRA1: The Distributed Teaming & Communication CRA emphasizes research that explores the rapid formation, real-time assessment, and dynamically optimized performance of distributed heterogeneous teams of warfighters as well as human-machine teams in order to enable rapid, agile & robust mission operations. Research areas will include: methods to enable the rapid formation of mission-effective heterogeneous teams, dynamic monitoring / assessment of team performance via optimal assemblage of novel and existing metrics, adaptive tactics for recovery from real or predicted team performance degradations, and novel distributed communication & collaboration tools, technologies and management methods that are responsive to variable network environments.

      • Dynamic Team Performance Assessment LOE1: Enable the rapid formation, real-time assessment, and dynamically optimized performance of distributed heterogeneous teams of warfighters as well as human-machine teams in order to enable rapid, agile & robust mission operations. Research areas include methods to support the rapid formation of mission-effective heterogeneous teams, dynamic monitoring of team performance via optimal assemblage of novel and existing metrics, and real-time contextual aids from team communication.

      • Team Optimization and Recovery LOE2: Design, develop, and evaluate team optimization and recovery technologies to enhance communication, coordination, and improve decision making among distributed teams. Research areas include interfaces to support joint tasking and team shared awareness (SA) across multiple domains as well as conversational AI technologies to enable high bandwidth natural communications.

    • Human Machine Interactions CRA2: The Human-Machine Interactions CRA emphasizes research to identify principles of human interaction with highly complex systems, including advanced automation & increasingly intelligent AI enabled machines. The goal of this research is to achieve and sustain decision superiority across complex & uncertain mission environments. Research areas include identifying, characterizing and overcoming key challenges to warfighter interactions with complex and intelligent systems such as situationally-adaptive interface design and usability, knowledge representation across sensory modalities, system observability & transparency, directability, joint cognitive decision making, and maintaining calibrated trust across changing conditions.

      • Rapid Joint-Cognitive Awareness LOE1: To develop human-centric interfaces and interaction strategies for improved AI/automation transparency, closed-loop adaptive systems that are responsive to warfighter state, and advanced techniques for effectively visualizing large, complex data sets.

      • HMI-enabled Decision Superiority LOE2: To develop capabilities for continuous planning for C2, next generation interfaces for complex intelligent platforms, and interfaces tailored for emerging Cognitive Warfare (CogWar) concepts.

  • Human Learning and Cognition (HLC) CTC2: The Human Learning and Cognition CTC enables more lethal Air and Space Forces through research on human multisensory perception, learning, information processing, and action. The research seeks to maximize mission effectiveness by (1) Establishing a persistent, global training and test ecosystem that creates the foundation for personalized, proficiency-based readiness for multi-capable Airmen and Guardians in joint all-domain operations, (2) Creating capabilities that allow teams of humans and machines to adapt and learn together in real time in training and operational settings, & (3) Advancing considerations of human performance in system development and operational planning with digital models of perception, cognition, & action.

    • Digital Model of Cognition CRA1: The Digital Models of Cognition Core Research Area emphasizes research to identify computational and mathematical mechanisms to represent human perception, information processing, and behavior, including the integration of models that reflect the role of internal and external factors that modulate performance efficiency and effectiveness. The goal is to develop holistic models that support quantitative understanding and prediction of mission effectiveness across domains and at different levels of abstraction for improved systems engineering, wargaming, and operational planning.

      • Holistic Models for Decision-Making LOE1: Develop models of cognitive systems that support quantitative understanding and prediction of mission effectiveness for decision superiority.

      • Information Mastery in Cognitive Warfare LOE2: Analytic methods, models, and tradecraft that enables operators to improve Information-Related Capability (IRC).

    • Learning and Operational Training CRA2: The Learning and Operational Training Core Research Area emphasizes learning and understanding in the context of evolving technology. This includes research to establish an ecosystem that maximizes mission effectiveness while minimizing costs by matching technologies to learning and performance needs; supporting high resolution human and system measurement and quantitative, proficiency-centric readiness assessment and prediction at the individual and team levels; and exploring how to enable human and machine co-learning to support mutual adaptation and understanding in human-machine teams.

      • Warfighter Learning Technologies LOE1: Research, demonstrate, & transition learning technologies, methods, & infrastructure for personalized, proficiency-based readiness.

      • Co-Learning for Adaptive Human and Machine Teams LOE2: Establish the foundation for interactive learning and collaborative training of humans and AI-enabled machines to enable uniquely effective human-autonomy teams.

• United States Air Force School of Aerospace Medicine (USAFSAM)

  Aerospace Medicine and Physiology

  • Aerospace Physiology: Solutions relating to physiologic assessment of aircrew in high altitude Fighters/Trainers.

    • Assessments of the physiologic response to exposures and stressors from the fighter/trainer environment; can cover any of the following: including effects of fluctuating pressure, high O2, air quality, breathing resistance, thermal burden, dehydration, rest/sleep (physical fatigue), cognitive fatigue, Aircrew Flight Equipment (AFE) integration (how AFE impacts in-flight physiology, and how AFE components interact with each other to impact physiology and aircrew performance), and combined stressors on performance and decision making in ground-based testing and operational environments, including the analysis of potential countermeasures to optimize pilot performance and eliminate sources of risk.

    • Solutions to sustain Aircrew performance in extreme environments.

    • Conduct comprehensive technology assessments of the current military health system simulators that can monitor and track physiologic responses from training student pilots.

    • There is a strong demand for wearables that are cross compatible across multiple systems to collect physiologic data, that are reliable and validated in the operational environment. Offerors are to conduct a comprehensive technology assessment of commercial off the shelf products, including their suitability for use in the operational environment and their validated measurement capabilities, to help aid aircrew and decision makers on what can be flown in the aircraft and what can be accurately collected from those sensors.

    • Musculoskeletal Injury Prevention and Treatment for Aircrew and Maintainers: Neck and back pain is a known occupational hazard for the high-performance aircraft community. The government seeks solutions, including tools to prevent, reduce, screen and diagnose musculoskeletal condition as well as alternative/integrative medicine approaches, for prevention or treatment of musculoskeletal injuries. Proposed solutions shall focus on providing reliable measurements to determine platform-specific neck/back dysfunction and improvements due to embedded care.

    • Gender-specific operational aircrew considerations

    • Assessment, modeling, detection, and/or mitigation Aircrew and Operator fatigue

  • Precision Medicine and Medical Standards: Development of solutions relating to the following areas:

    • Surveillance of conditions, indications, clinical practice guideline adherence, and outcomes to support cost benefit analyses for Air Force population.

    • Genomics for mishap investigations (gene expression, subtracting human and molecular autopsy).

    • Studies providing data to support evidence-based aerospace medicine standards and waivers.

    • Psychological Performance and Mental Health (solutions should relate to at least one of the following areas)

      • Mental health and psychological disorders amongst airmen and potential influence on readiness and retention.

      • Neurocognitive diversity; cognitive testing and correlates with mental health and other outcomes.

      • Assessment of the feasibility of integrating the use of personality data and wearable technology to facilitate adjustment and success during career specific training. Personality assessments and wearables both as tools to facilitate readiness via positive change, wellbeing, and performance by increasing self-awareness.

  Public Health and Preventative Medicine

  • Development, optimization, and validation of pathogen detection methodologies

  • Cancer analysis in the Air Force population

    • Development and evaluation of prototypes that can identify carcinogenic toxins or hazardous materials associated with military flight operations from shipboard or land bases or facilities.

    • Development and evaluation of prototypes that can identify exposures to ionizing radiation and nonionizing radiation from which airmen could have received increased radiation amounts.

    • Establishment of guidelines for carcinogen exposure as it relates to demographics for each airman to include duty stations, duties and aircraft flow.

    • Establishment of guidelines that outline the duties and potential exposures of airmen that are associated with higher incidence of cancer.

    • Development and evaluation of screening tools and/or methods that relate to carcinogen exposure to airmen.

  • Assess methodologies to prevent wound infection.

  • Assess infectious disease conditions in Air Force populations.

  Occupational Medicine and Bioenvironmental Engineering

  • Enhancement of capabilities to detect, measure, and assess occupational and environmental health hazard contaminants and extreme environmental conditions.

    • Assess technologies to enhance capabilities to detect and identify chemical, biological, toxins, radiological, directed energy, poisons and physical hazards on surfaces (including soil and powder), in liquids and in the air in near real-time at the detector's point of operation and notify end user of risk.

    • Assessment of Aviation-Specific Exposures

    • Develop, test and evaluate real-time health threat surveillance and reporting system inclusive of all available health information/databases to identify risks/outbreaks and provide decision support to operational commanders.

  • Evaluation/development of mitigation technology capable of reducing or eliminating occupational and environmental health hazard risks.

  En Route Care/Expeditionary Medicine/Prolonged Field Care: Needs in this area include medical capabilities to support in route care to/from remote, austere settings, and in extreme environments.

  • Training methodologies to improve operational readiness for individuals and teams responsible for delivering basic and advanced en route care capabilities within the aeromedical evacuation system.

  • Technology assessment/development to support the Air Force Surgeon General’s medical modernization priorities with a focus on modernizing outdated technologies and techniques to promote en route care growth/preparation for future peer/near-peer conflicts involving mass casualty care.

  Education and training technologies and methodologies to support efforts to generate, develop, and maintain skillsets across the AOME.

  Applications of data science to analyze medical and operational data and outcomes across the AOME, which may include implementation of AI and machine learning to answer operationally relevant questions.

Are there any additional benefits I would receive?

Beyond direct funding, CHEERS participation offers significant indirect advantages for growth and strategic positioning:

Government Validation and Credibility:
Selection under AFRL’s CHEERS program signals strong technical merit and alignment with Department of the Air Force human performance priorities—an endorsement that enhances your credibility with defense primes, OEMs, and investors.

Enhanced Market Visibility and Notoriety:
Awardees benefit from exposure in federal announcements, AFRL communications, and defense industry press—raising visibility and positioning your company as a trusted innovation partner in the human-performance and aerospace ecosystem.

Ecosystem Access and Collaboration Opportunities:
CHEERS projects operate within a national network that includes top-tier military researchers, AFRL directorates, and medical readiness centers. This access often leads to future R&D partnerships and contracting opportunities.

Stronger Exit and Acquisition Potential:
By advancing your technology with nondilutive support and demonstrating government-backed validation, companies can increase valuation and strengthen their position for acquisition or strategic investment by defense and medical technology leaders.

What is the timeline to apply and when would I receive funding?

• White Paper Deadline: Rolling through September 30, 2027. This means applicants should apply as soon as possible before funds are fully expended.

• Review Period: Technically 180 days for AFRL to review white papers - but it could also be reviewed faster.

• Proposal Invitation: AFRL will invite full proposals only from offerors whose white papers align with Air Force needs.

• Proposal Deadline: Defined in each Request for Proposal (RFP).

• Award Timing: Awards are issued once funds become available; no awards are made until funding is confirmed.

Where does this funding come from?

Funding is issued by the Air Force Research Laboratory (AFRL) under the following authorities:

• Open Period 1: 10 U.S.C. 4001 / FAR 35.016 (Broad Agency Announcement).

• Open Period 2: 10 U.S.C. 4023 (Procurement for Experimental Purposes).

These authorities allow AFRL to fund both research contracts and prototype agreements, depending on project maturity and experimental needs.

Who is eligible to apply?

1. Open to U.S. companies, universities, and research organizations.

2. Foreign participation is allowed subject to export and security controls.

3. Cost sharing is not required.

4. Offerors may submit multiple white papers, provided each represents a distinct technical approach.

What companies and projects are likely to win?

Offer innovative, defense-relevant solutions that measurably enhance warfighter performance, medical readiness, or operational resilience.

1. Demonstrate clear technical feasibility, transition potential, and sound risk mitigation.

2. Show strong alignment with AFRL’s human effectiveness and medical research priorities.

3. Have experienced teams capable of performing under experimental or prototype authorities.

Evaluation criteria (in descending order of importance):

1. Uniqueness and innovation.

2. Understanding of scope and technical approach.

3. Technical soundness and team qualifications.

4. Transition potential.

5. Cost realism and value.

Are there any restrictions I should know about?

• Export Control: Some projects may require U.S. or Canada Joint Certification (DD 2345).

• Human/Animal Subjects & Hazardous Materials: Approval requirements vary by project and will be outlined in each solicitation.

• S&T Protection: AFRL’s Science and Technology protection and OPSEC rules apply.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive white paper + full proposal will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

How much would BW&CO Charge?

Our full service support is available for the White Paper for $3000. Full proposal quoted upon invitation.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

View the Funding Announcements:

• Continuing Human Enabling Enhancing Restoring and Sustaining (Master Announcement)

• CHEERS Open Period 1 - All Technical Areas

• CHEERS Open Period 2 - All Technical Areas

CHIPS Research & Development Office (CRDO) Broad Agency Announcement

Executive Summary:

The CHIPS Research and Development Office (CRDO) at NIST is awarding at least $10 Million per award—via Other Transaction (OT) agreements—for research, prototyping, and commercialization projects that advance U.S. microelectronics, including work tied to AI, quantum, biotechnology/biomanufacturing, commercialization of innovation, and standards. Applications are accepted on a rolling basis which means companies should submit white papers ASAP. Receive a complimentary assessment to see if your company and project is a fit for this funding.

How much funding would I receive?

Budgets should be at least $10 million and reflect actual project needs. CRDO may fund only a portion of total costs and can fund multi-phase projects incrementally based on satisfactory progress, mission fit, and availability of funds. Awards are negotiated as OT agreements. Cost sharing is not required for all awards, though CRDO may choose to fund only part of a project.

What could I use the funding for?

Eligible activities include research, prototyping, and commercialization efforts that strengthen U.S. leadership and the domestic semiconductor ecosystem. Priority topic areas include:

• Semiconductors (e.g., advanced testing/assembly/packaging, next-gen devices and memory, design co-optimization, automation/AI in fabs, secure supply chains)

• Application of AI for advanced microelectronics R&D (e.g., compute efficiency, edge AI, cryogenic ops, fab acceleration)

• Application of quantum technology (e.g., scalable quantum computing, quantum networks/sensing, domestic production of quantum hardware)

• Application of biotechnology/biomanufacturing for microelectronics (e.g., bioelectronics, implantable devices, scaling domestic bio-electronics manufacturing)

• Commercialization of innovations (e.g., adopting and commercializing federally funded discoveries, including through consortia)

• Standards development (e.g., quantum manufacturing, data/design/provenance/security standards).

Are there any additional benefits I would receive?

Beyond the formal funding award, there are significant indirect benefits to receiving a CHIPS R&D Office (CRDO) award:

• Government Validation and Credibility:
  Being selected by NIST’s CRDO signals strong technical credibility and alignment with national semiconductor priorities. That stamp of approval often accelerates partnerships with OEMs, primes, and investors who trust government-vetted innovation.

• Enhanced Market Visibility and Notoriety:
  Award recipients frequently receive public recognition in federal announcements, CHIPS R&D Office communications, and industry press. This visibility helps position your company as a trusted, strategic player in the microelectronics ecosystem.

• Ecosystem Access and Collaboration Opportunities:
  CRDO-funded projects are part of a national innovation network—creating opportunities to collaborate with leading researchers, manufacturers, and other awardees. Such access can unlock supply chain partnerships and future contracting opportunities.

• Stronger Exit and Acquisition Potential:
  By maturing technology under nondilutive support and demonstrating government-backed validation, recipients often achieve greater value at exit—especially when positioning for acquisition by larger defense, semiconductor, or AI hardware firms.

What is the timeline to apply and when would I receive funding?

Applications (beginning with a required White Paper) are accepted on a rolling basis through September 30, 2029 via Grants.gov. If a White Paper shows sufficient merit and relevance, CRDO may invite a Pre-negotiation Package (detailed technical and cost proposal). Awards are made on a rolling basis as packages are evaluated and terms are finalized. A specific funding disbursement date is not specified. Maximum project period is up to 5 years.

Where does this funding come from?

U.S. Department of Commerce, NIST—through the CHIPS Research and Development Office (CRDO)—under authority including 15 U.S.C. § 4656 and related CHIPS R&D statutes/policies. Assistance Listing: 11.042 CHIPS R&D.

Who is eligible to apply?

Domestic entities only: for-profit organizations, non-profits, accredited higher-education institutions, FFRDCs, and Federal entities (with conditions). Individuals and unincorporated sole proprietors are not eligible. Subawardees may include the above and foreign partners not otherwise prohibited, subject to security and other requirements.

What companies and projects are likely to win?

Projects that:

• Advance national and economic security and U.S. technology leadership by strengthening domestic semiconductor supply chains and workforce

• Demonstrate strong scientific/technical merit with clear deliverables

• Show feasibility (experienced team, realistic costs, risk mitigation)

• Have credible commercial viability (market demand, transition plan)

• Show financial viability (sound capex, financial health, credible capital plan).

Are there any restrictions I should know about?

• Domestic production and control of IP: Foreign entities can apply but should develop and own the IP in the US.

• Security restrictions: no funds to foreign entities of concern; compliance with research security disclosures; prohibition on malign foreign talent recruitment programs

• CRDO may require return-on-investment instruments (e.g., equity, warrants, IP licenses, royalties/revenue sharing)

• Scope: general AI projects not directly tied to advanced microelectronics R&D are out of scope

• Reporting: financial, performance, and/or technical reports are required.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission under this BAA will likely take 120–180 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under CHIPS R&D initiatives.

How much would BW&CO Charge?

Our support is available at $300 per hour, with most CRDO proposal projects requiring 80–100 hours of expert support from strategy through submission.

For non-VC backed startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

• Webinar - How to Win $10M for R&D from the New CHIPS CRDO BAA

• View Solicitation on Grants.Gov

DARPA Biological Technologies Office (BTO) Broad Agency Announcement

Executive Summary:

DARPA’s Biological Technologies Office (BTO) is accepting rolling proposals to fund transformative biology-enabled capabilities for national security. An abstract is required before a full proposal, and both abstracts and proposals are accepted until September 30, 2026. For selected proposals ≤$2,000,000 that opt into the accelerated path, awards can be made within 30 days of selection. Companies targeting this BAA should submit an abstract as soon as possible as they are reviewed on a rolling basis.

How much funding would I receive?

Funding levels are not pre-set; BTO anticipates multiple awards across topics. An optional accelerated award path is available for selected proposals not exceeding $2,000,000 total, using model agreements tailored for small and large businesses.

What could I use the funding for?

Research & Development proposals that leverage biological properties and processes to revolutionize our ability to protect the nation’s warfighters. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of practice.

• General Topics

  • Biological and/or chemical technology topic areas that fit the national security scope of BTO’s mission.

  • Research into market opportunities, constraints, and communities affecting financing and commercialization of bioindustrial and biomedical technologies.

• Machine Learning (ML) and Artificial Intelligence (AI)

  • Developing and advancing our understanding of the impact and principles underlying biological data generation, assessment and incorporation into the biological foundation models, or mixed-mode foundation models. This includes taking theoretical approaches as well as understanding the scaling laws of these data for various types of models.

  • Advancing the capabilities of broad or narrow biological and/or chemical or mixed-mode foundation models far beyond the state of the art.

  • Developing and proving non-experimental models or hybrid experimental/non-experimental assessment strategies for biological foundation model assessment.

  • Exponentially accelerating the time scale of biological system simulation from the subcellular through multicellular, organismal and environmental systems, including for threat prediction, impact assessment, and attribution modeling.

  • Developing ML and AI-enabled technologies to improve the accuracy, precision, and efficiency of warfighter decision-making in complex and dynamic environments (e.g., on and off the battlefield), including for real-time threat assessment and response planning.

  • The development of virtual testbeds, digital twins, and/or synthetic data to accelerate or improve the predictive modeling of human performance.

• Combat Casualty Care

  • Developing novel diagnostic, prophylactic, and therapeutic approaches for warfighter injury that can be provided even in austere settings and extreme conditions.

  • Developing capabilities and technologies that enhance the ability of non-skilled service members to perform essential medical tasks closer to the point of injury, reducing dependence on highly trained personnel through assistive devices.

  • Developing decision support tools that algorithmically optimize the alignment of medical requirements and resources in complex, data-constrained mass casualty scenarios to enhance near-real-time situational awareness and command and control (C2) planning and execution.

  • Development of capabilities and technologies that enhance the ability of non-skilled service members to perform essential medical tasks closer to the point of injury, reducing dependence on highly trained personnel through assistive devices.

• Human Performance

  • Understanding and improving treatment of and resilience in neurological health, transformative neural processing, fatigue, cognition, and optimized human performance and teaming, including in extreme stress conditions.

  • Discovering interventions that utilize biotechnology, biochemistry, molecular biology, microbiology, neuroscience, psychology, cognitive science, social and behavioral science, and related disciplines to assess and optimize human performance and teaming.

  • Developing and leveraging technologies to advance continuous or near-continuous monitoring of physiology to elucidate mechanisms of human readiness, cognitive status, and resilience.

  • Understanding and improving interfaces between the biological and physical world to enable seamless biohybrid systems and devices.

  • Developing approaches to enhance physiological resilience, performance, and survivability in extreme conditions (e.g., cold weather, extreme heat, high altitude).

  • Identifying technologies and tactics to increase or accelerate the impact of training regimens while reducing the risk of injury.

• Materials, Sensors, Processing

  • Designing novel materials, sensors, or processes that mimic or are inspired by biological systems.

  • Creating tools such as foundation models or prediction engines to understand the underlying rules defining biomolecular and biomaterial or hybrid biotic/abiotic material structure/function properties (individual properties or groups of properties) in order to predict desired outcomes for novel material development. Importantly, these predictions should hold from the molecular scale to the macro scale.

  • Developing new computational and experimental tools and predictive capabilities for engineering of biological systems, such as cells, tissues, organs, organisms, and complex communities, to both develop new products and functional systems, as well as to gain new insights into underlying mechanisms.

  • Developing technologies to leverage biological systems and enhance the acquisition and maintenance of critical and strategic organic and inorganic materials.

  • Understanding and leveraging complex biological systems into underlying functional rules and processes to provide models that govern interactions of biological systems from biofilms to organs or ecosystems.

  • Developing new platform technologies that integrate, automate, and miniaturize the collection, processing, and analysis via direct or indirect interrogation of biological and chemical samples.

  • Developing hybrid biological/engineered systems that integrate biological organisms, components, biologically-encoded circuitry, biogenic materials, or exploit biological phenomena to surpass capabilities of abiotic equivalents.

  • Developing novel biological sensor platforms with reduced size, weight, and power requirements of equivalent electro-optical or electro-mechanical systems with orders of magnitude increase in equivalent performance.

• Security, Safety, and Surveillance

  • Developing new technologies and approaches to ensure the biosafety and biosecurity of biological hardware and data. Ensuring the safety and security of AI technologies that accelerate biological research and development processes.

  • Developing innovative technologies to detect, characterize, treat, prevent, and forecast the effects of novel, engineered, or natural emerging pathogens that have the potential to cause significant health, economic, and social burdens, to prevent their spread and enable understanding of their origin.

  • Developing ML, AI approaches, and advanced data analytics for the rapid analysis, interpretation, identification, attribution, and origin tracing of large-scale, disparate biological and environmental surveillance data streams, enabling anomaly detection, pattern recognition, scalable detection, and predictive analytics to identify emerging threats or anomalous events and provide early warning and anticipatory action against natural or manmade biological threats.

  • Advancing technologies for determination and attribution along with data provenance analysis at chemical, isotopic, genetic, and community structure levels.

  • Developing novel sensing, surveillance, and processing technologies (including in-situ and remote modalities) to detect, identify, monitor, and analyze weak biological signals of emerging pathogens (novel, engineered, or natural) at all scales, including their secondary effects on the environment.

  • Developing new technologies and data analytics to support next-generation surveillance, detection, identification, and attribution of human and agricultural pathogens at scale and in near real-time.

  • Developing novel in-situ or remote sensing and surveillance technologies at the global, regional, and local scale that detect and identify novel, engineered, and/or natural emerging pathogens to prevent their spread or understand their origin.

• Biomedical & Biodefense

  • Developing new technologies for rapid, automated, and resilient manufacturing, delivery, and distribution of critical molecules for applications in therapeutics, chemical, and biological defense.

  • Developing new technologies to support next-generation cellular therapeutic applications.

  • Developing new platform technologies for targeted, effective, spatiotemporally controlled delivery of large and small molecules and biologics.

  • Leveraging biotechnology to create new platform solutions that combat antimicrobial resistance, generate novel drug and cell-based therapeutics, and treat warfighter injury and illness.

Are there any additional benefits I would receive?

Beyond the formal award, there are significant indirect benefits to receiving a DARPA Biological Technologies Office (BTO) contract or agreement:

• Government Validation and Credibility:
  Being selected by DARPA—the Department of Defense’s premier innovation agency—signals extraordinary technical credibility and alignment with national security priorities. This “DARPA validation” often accelerates partnerships with primes, OEMs, and investors who trust government-vetted innovation.

• Enhanced Market Visibility and Notoriety:
  Award recipients frequently receive public recognition through DARPA announcements, defense innovation conferences, and press coverage. This visibility helps position your company as a cutting-edge player in defense biotech and deeptech, attracting further investment and talent.

• Ecosystem Access and Collaboration Opportunities:
  DARPA performers gain access to the BTO’s extensive network, including technical advisors, transition partners, and resources. These programs support contractor readiness, compliance, and downstream transition—opening doors to additional government and industry contracts.

• Nondilutive Growth and Strategic Leverage:
  Because funding is nondilutive, companies can scale and validate core technologies without giving up equity. This validation and maturity achieved under government sponsorship often lead to higher valuations and greater leverage in future fundraising or acquisition discussions.

• Faster Execution and Credible Track Record:
  With DARPA’s accelerated contracting path, companies can move from selection to award in as little as 30 days—establishing a record of execution under one of the most selective R&D programs in the world, which strengthens competitiveness for future federal or dual-use opportunities.

What is the timeline to apply and when would I receive funding?

Abstracts are accepted on a rolling basis until September 30, 2026, 4:00 PM ET (abstract and DARPA invitation are required before any full proposal).

Full proposals are accepted on a rolling basis until September 30, 2026, 4:00 PM ET.

Accelerated option (≤$2M) awards may be issued within 30 days of selection notification if you submit the required election/attestations and use the model agreement.

Where does this funding come from?

The Defense Advanced Research Projects Agency (DARPA), Biological Technologies Office

Who is eligible to apply?

All responsible sources—U.S. and non-U.S.—may submit, except FFRDCs, UARCs, and Government entities (incl. National Labs), which are not eligible as prime proposers. NAICS: 541714 (biotech R&D). Submissions must comply with U.S. security, export control, and related laws.

What companies and projects are likely to win?

The scoring criteria reward proposals that:

1. Present a bold, high-impact technical approach. Proposals that merely increment the state of practice are explicitly out-of-scope;

2. Directly advance DARPA’s national-security mission; and

3. Show credible cost/schedule realism with clear deliverables and risk-mitigation. Prior experience executing similar efforts and leveraging relevant prior research strengthen competitiveness.

Are there any restrictions I should know about?

• Abstract is mandatory; DARPA must invite a proposal before it will be reviewed.

• Compliance areas include CUI handling, cyber (e.g., NIST SP 800-171 assessments), export controls, and human/animal research approvals where applicable.

• Certain entities/equipment (e.g., Kaspersky, certain telecom/DRONE restrictions, ByteDance apps) are prohibited by clause.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission under this BAA will likely take 120–160 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $15,000 Project + a 5% Success Fee.

Fractional support is $300 per hour, with most DARPA proposal projects requiring 80–100 hours of expert support from strategy through submission of full proposal.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

• Webinar - New Biotech Funding: $2M from the DARPA BTO Office

• See solicitation on Grants.Gov